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ABSTRACT
The immune system plays a dynamic role in cancer progression. The theory of
immunoediting suggests that the relationship between the tumor cell and the immune cell
is one that is in flux: initially highly active and responsive to tumor antigen to one that has
escaped immune responsiveness. Once the tumor has formed and effectively “escaped”,
there are multiple mechanisms that work against a conventional immune response. The
tumor cell clones that have escaped the elimination phase are those that are less
immunogenic. These clones downregulate MHC, have increased apoptosis through
DAMP-driven mechanisms, and suppressive cell phenotypes are driven through cytokinedriven cues and innate feed-forward mechanisms. This project aims to understand three
different mechanisms of tumor-induced immune suppression: the first, a model of lung
adenocarcinoma, exploring innate NK subversion by repression of the NKG2D-MICA/B
axis; the second, a model of mammary carcinoma used as a basis to explore differences
in NK trafficking and exclusion from the tumor microenvironment due to upregulation of
inhibitory signaling mediators; the third, a mechanism of T cell suppression induced by
excessive production of danger associated molecular pattern (DAMP) S100A9 in
Myelodysplastic Syndromes (MDS).
Lung Cancers of all subtypes are the leading cancer death in both men and women
in the United States. While progress has been made in developing immunotherapies, we
chose to focus on basic mechanisms of immunosuppression in order to identify ways to
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reinvigorate tumor-immune responsiveness. Micro-RNAs (miRs) function via RNA
interference and are implicated in cancer development and progression due to their
effects on genes involving the cell cycle, apoptosis, and metabolism. Our group has
previously shown that Transforming Growth Factor-beta (TGFβ) inhibits NK cell function
by means of inducing miR-183 and subsequent repression of DAP12, thus halting NK cell
signaling. Here, we found that NKG2 ligand MICA/B which is normally upregulated in
situations of stress or damage is suppressed in the presence of high levels of miR-183.
This miR, employed by the suppressive TGFβ, renders NK cells dysfunctional by
depleting MICA/B from the tumor cell itself so that the NK cell cannot recognize it through
activating receptor NKG2D. This is a profound mechanism that hits at one of the earliest
effector mechanisms in the tumor microenvironment.
Micro-RNA 155 is another oncomir that is expressed in NK cells and other
leukocytes,

where

it

is

upregulated

by

inflammatory

stimuli

in

the

tumor

microenvironment. SH2-containing inositol polyphosphate 5-phosphatase (SHIP-1)
negatively regulates interferon gamma production in NK cells and regulates the actin
cytoskeleton, having diverse effects on NK cell motility. SHIP-1 is a defined target of miR155, and thus SHIP-1 is decreased in the context of excessive miR-155 expression. This
miR is thus important to NK cell function, as we showed in our work that in the absence
of this miR, there exists a dysfunctional NK cell that cannot traffic or produce proper
amounts of cytokine in response to normal stimuli. Here, we found that miR-155 regulates
chemotaxis and NK tumor infiltration downstream of SHIP-1 using a mouse model of
mammary carcinoma. This is a basic science mechanism that teases apart the complexity
of the relationship between this miR and leukocyte trafficking into the tumor bed,
vii

identifying another mechanism of immune subversion in this case mediated by a lack of
trafficking present in the inflammatory tumor microenvironment, and thus has applicability
to many tumor types.
MDS are a disease driven by excessive inflammation secondary to peripheral
blood cytopenias and hypercellular bone marrow. This disease is predominately driven
by an excess of myeloid derived suppressor cells (MDSC) and suppressive cytokines that
dampen conventional mechanisms of immunity. The role of T cells in the disease is
incompletely understood. Here, we report on a newly identified mechanism of T cell
suppression in the disease mediated by DAMP S100A9 through the Pattern Recognition
Receptor (PRR) Receptor for Advanced Glycation Endproducts (RAGE). Rather than
inducing a potent immune response as DAMP/PRR signaling should, we uniquely found
that T cells are inhibited in their function when exposed to exogenous DAMP signaling. T
cell proliferation is almost completely shut down, and interferon gamma production is
halted.
While many PRRs are present on adaptive cells, RAGE was found to be exclusive
to CD4+hi T cells, whereby S100A9 signals through. These T cells did not express any
lineage specificity, and produced normal amounts of cytokine when activated with antiCD3/28. Treatment with S100A9 was able to induce RAGE expression on these T cells,
indicating a positive feed forward loop. This RAGE expression was dynamic and
decreased rapidly after T cell receptor (TCR) engagement, indicating that this
RAGE/S100A9 signaling response may act as a pre-activation checkpoint for the T cell
prior to responding to antigen. We found that RAGE+ T cells are significantly increased
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in the bone marrow of patients with MDS, and thus this may represent a way to capitalize
on a lack of T cell responsiveness in a disease with typically limited treatment options.
The work presented here furthers our understanding of tumor-immune biology from
both a basic science approach and more translational approaches. The questions asked
throughout this work attempt to unpack the complexity of the relationship between the
immune cell and the cancer cell in a push-pull that, given future efforts for translation, can
improve outcomes and in the case of the RAGE/S100A9 axis, be translated into new
therapies (Fig. 1).

Figure 1: Overview of the Dissertation: Integration of the three projects presented within the dissertation.
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CHAPTER ONE:
INTRODUCTION
Introduction to NK cells
Natural Killer (NK) cells are an innate effector lymphocyte cell subtype that kill and
produce cytokine in a non-MHC restricted fashion (1). NK killing is dependent on a
balance of positive and negative inhibitory signals or by the loss of major
histocompatibility complex (MHC) class I (2). A conventional NK cell phenotype in
humans is defined as CD3-CD56+, though NKT cell subsets that are double positive
(CD3+CD56+) exist and are outside the scope of this dissertation (3). Murine analogs
for these two subsets are CD3-NK1.1+ (or in the case of NKT CD3+NK1.1+) (4). Human
NK cells can be further stratified based on their CD56 expression into CD56dim(CD16+)
vs CD56bright (CD16-/dim) subpopulations. The CD56dim population is typically peripheral
blood resident and the more cytotoxic NK subpopulation, and the CD56bright more
secondary lymphoid organ resident and heavy producer of cytokine, typically Interferon
Gamma (IFNγ), Tumor Necrosis Factor Alpha (TNFα), and Interleukins-2,12,15, and 18
(5, 6).
NK cells display a wide variety of activating and inhibitory receptors that function
to maintain a balance against effector function against healthy tissue. Situations of cell
stress such as transformation induce expression of NK activating ligands such as MHC
Class I and Chain-Related Protein A and B (MICA/B) on the tumor cell, leading to lysis of
1

the tumor or stressed cell (7-9). This is relevant in all contexts of health and disease
including autoimmunity, viral infection, and cancer. Mechanisms of NK cell cytolysis can
either be through release of lytic granules on lipid rafts such as perforin and granzyme B
or through engagement of receptor/ligand pairs such as Fas/FasL which induce apoptosis
secondary to caspase activation (10, 11). NK cell activation itself leads to production of
numerous cytokines that can shape the immune milieu. This informs the subsequent
immune response through T cell polarization (discussed further under T cell header
below) and reinforces antigen presentation through IFNγ production through MHC
upregulation (12-15).

NK cells and Cancer
While a lack of MHC should be enough for the NK cell to recognize and lyse a
given cell based on the missing-self hypothesis, tumor cells have evolved potent
mechanisms to subvert NK cells through upregulation of ligands for inhibitory receptors.
In addition to the NK activating/inhibitory receptor pairs, much like T cells, NK cells
express checkpoint receptors such as PD-1 and TIM3, which engage with PD-L1/2 or
Gal9 on the tumor cell. Sustained engagement and signaling with these receptor/ligand
pairs leads to NK cell exhaustion and dysfunction (16-18). PD-1 blocking antibodies have
been found to reinvigorate the suppressed NK cell similar to that of T cells (19). NK cells,
like their adaptive cytotoxic counterparts, can be uniquely used as platforms for adoptive
cell transfer. In earlier years, IL-2 activated lymphokine activated killer (LAK) cells were
used as a platform for immunotherapy (20, 21), and in more recent years, these NK cells
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have been endowed with chimeric antigen receptors (CARs) to direct these cells to
recognize and kill tumor directly through specific antigen recognition (22, 23).
NK cells are found amongst tumor infiltrating lymphocytes (TIL) in melanoma,
breast, colorectal carcinomas as well as other malignancies, and while their presence
may be a positive prognostic indicator, the functional phenotype inside the tumor varies
in terms of active functional output (24).
Identifying basic mechanisms of NK cell suppression can lead to reinvigoration of
the suppressed NK cell phenotype. Studying tumor cell induced factors that may affect
NK cell function is the basis for Chapter 2.

microRNAs and Cancer
MicroRNA’s (miR) are small (19-24 nucleotide) noncoding RNAs that regulate gene
expression through posttranscriptional interference by RNA repression. To function, they
bind to a region at the 3’ UTR of their target mRNA. They were originally thought to be
noise in the genome but were later discovered to be tightly regulated and important in all
aspects of development and normal hematopoiesis (25). MiRs have been found to be
dysregulated in multiple diseases and have been extensively linked to cancer. In
particular, they have been shown to be involved in the regulation of oncogenes, tumor
suppressor genes and genes associated with metastasis (26). The phrase “oncomir” was
coined to describe oncogenic miR’s which themselves have been shown to drive cancers.
Many of these miRNA expression patterns have been linked to negative outcomes across
various cancer subtypes, and specific miR expression patterns have been tightly tied to
specific cancer subtypes (27). These expression patterns have been proposed for use as
3

cancer biomarkers for stratification and prognosis. Over 2000 miRs have been identified
at this time, and many have sequence homology with each other and are referred to as
clusters (28). Our past work focuses on the cluster miR-183-96-182, which despite
playing normal roles in organogenesis, has been associated with the prognosis of liver,
breast and lung cancers when overexpressed (29-32). MiR-183 has been found to be
inducible in tumors through cytokine

TGFβ expression which dominates in many

suppressive tumor microenvironments (33, 34). Our group has shown that it suppresses
NK cell function against tumor through the suppression of NK adaptor molecule DAP12
(35). Thus miR-183 can directly suppress anti-tumor immunity. This older work and more
our recent follow-up work will be extensively discussed in Chapter 2.
Additional work discussed in this thesis focuses on miR-155. miR-155, like miR183 is expressed in leukocytes and is upregulated by inflammatory stimuli such as TNFα
and IFNγ (36, 37). It is overexpressed in various cancers including leukemias and
lymphomas as well as many solid tumors (38-42). SH2-containing inositol polyphosphate
5-phosphatase (SHIP-1) is expressed in NK cells, where it negatively regulates IFNγ
production, and is a target of miR-155 (43, 44). SHIP-1 is absolutely critical for NK cell
development and function, and overexpression of miR-155 decreases SHIP-1 expression
(45). This oncomir has been studied extensively in T cells, where it has been found to
promote effector T cell responses, and in knockout experiments, the T cells are rendered
dysfunctional (46, 47). In both NK cells and T cells, miR-155 is cytokine and activation
responsive (48-50). These past reports have demonstrated the importance of this miR in
NK cell functionality, but we were intrigued by the fact that excessive miR-155 leads to
an increase in SHIP-1, and chose to interrogate this further utilizing a miR-155 knockout
4

mouse. In this work we identified a physiologic role of miR-155 in NK cell chemotaxis that
leads to reduced tumor infiltrating NK cells and thus reduced tumor clearance in a mouse
model of mammary carcinoma. This work will be discussed in Chapter 3.

Myelodysplastic Syndromes
Myelodysplastic syndromes are a group of diseases of aging, affecting between 5.3 and
13.1 cases per 100,000 people (51-53). Central to the disease is ineffective
hematopoiesis driven by mutational burden and inflammatory aging (inflammaging)
associated increases in suppressive populations such as MDSC and Treg as well as an
increased rate of apoptosis (54-64). This increased apoptosis leads to cytopenias noted
in the peripheral blood, and a hypercellular bone marrow with increased blasts (immature
myeloid progenitor accumulation)(63-70). MDS affects those >65 years of age and has a
grim prognosis of six months once it approaches high risk disease staging. Up to onethird of patients with MDS will transform to acute myeloid leukemia (AML), thus this
disease deserves much focus in research to determine mechanisms contributing to
issues with immunosurveillance and ways in which we can halt disease progression(71).
MDS is staged using the International Prognostic Scoring System (Revised) (IPSSR). Patients are staged from 0-6 (ranging from very low risk to very high risk) based on
cytogenetics (mutational status), blast percentage, hemoglobin, platelets and absolute
neutrophil count (ANC) (72, 73). Patients with lower risk disease can live for many years
prior to transformation occurring, and with these patients the focus is more about
symptom management with less intense therapies (74). With the higher risk patients, the
risk of transformation is very high, and the survival time drops to months. In these patients,
5

oftentimes stronger cocktails of chemotherapeutics are utilized or allogeneic bone marrow
transplant (BMT) (75).
Mutational burden of MDS is often a driver of disease, affecting myeloid
progenitors and thus impacting those cells originating from this hematopoietic lineage.
Patients that progress to AML have been found to have a higher somatic mutational
burden than those who do not. The most common somatic mutations in MDS include the
following genes: DNA Methyltransferase 3A (DNMT3A), Serine and Arginine Rich
Splicing Factor 2 (SRSF2) Janus Kinase 2 (JAK2) and TP53. Additional sets of germline
mutations have been identified as associated with MDS including DEAD-Box Helicase 41
(DDX41), Runt Related Transcription Factor 1 (RUNX1) and GATA-Binding Protein 2
(GATA2). A common mutation seen in the disease is deletion of chromosome 5q (Del
5q), which is a more indolent subset of MDS that predominately affects women (54).
MDS treatment is variable and specific to disease staging. Many patients are
asymptomatic when diagnosed and evidence of disease was determined through anemia
noticed on a complete blood count (CBC) during a routine physical. Other symptoms
include easy bruising, fatigue, weakness and bone pain. Watchful waiting is an approach
taken often given that MDS is an incurable disease and not enough evidence for treatment
at earlier asymptomatic stages exist. When the decision is made to treat, it is often
focused on symptom control.
Typically, the first treatments decided on are hypomethylating agents such as
azacytidine and decitabine, growth factors such as epotein to stimulate erythropoiesis,
GM-CSF to stimulate neutrophils, immunosuppressive therapies, and in the case of Del
5q cases, lenalidomide (74).
6

The hypomethylating agents inhibit DNA methyltransferases and have been
shown to improve overall survival due to their response rate to treatment of 40-60% often
leading to a decrease in dependence on blood transfusion. Unfortunately, some patients
become resistance to the hypomethylating agents currently used in the clinic (76-78).
Immunosuppressive therapies are useful in lower risk disease. The two most
common therapies in this classes are Anti-Thymocyte Immunoglobulin (ATG) and
Cyclosporine. ATG is reactive against T cells, and this drug is used to suppress the
smoldering inflammation present in MDS that increases apoptosis and leads to
cytopenias. Cyclosporine functions similarly in that it blocks T cell activation. Oftentimes
ATG and cyclosporine are used in combination as a two-hit punch against T cell mediated
inflammation (79). This also helps as many MDS patients have comorbidities with T cell
mediated

autoimmune

disease

that

leads

to

a

worse

prognosis,

and

so

immunosuppression is indicated due to both diseases (80, 81).
Immunomodulatory (IMiD) drugs are thalidomide analogues. These drugs have an
unknown mechanism but is anti-inflammatory and pro-erythropoetic. Unlike the
immunosuppressive therapies, IMiDs increase the function of T cells but with the
production of less aggressive inflammatory cytokines such as IL-10. While it is typically
used in Del 5q patients with great success, it is under investigation in non-Del 5q patients
and has shown some success, though it is limited in comparison to the high response
rate seen in Del 5q MDS. These drugs lead to decreased transfusion dependence due to
a strong erythropoetic response (79, 82).
Cellular therapies are currently under investigation for MDS. The oldest cellular
therapy currently in use is allogeneic bone marrow transplant. This is the only real curative
7

therapy and is typically only used for those patients with later stage disease. Despite
being curative, those patients with TP53 mutations still have a worse prognosis (83-86).
Newer cellular therapy options include Chimeric Antigen Receptor T cell
immunotherapy (CAR-T), which are a promising treatment for many hematologic
malignancies. CAR-T utilize a T cell engineered to express the scFv of an antibody
targeting a given tumor associated antigen (TAA) fused to CD3ζ via a linker. This
reengineers the T cell with a new directed specificity, and upon reinfusion, these T cells
specifically target their new antigen leading to tumor cytolysis and ideally, tumor control
(87). They have been approved to treat acute lymphoblastic leukemia (ALL) and diffuse
large B cell lymphoma (DLBCL), and these approved therapies both target CD19 (88-90).
For MDS, CAR-T have been developed against the IL-3 receptor (CD123) and NKG2D
ligands and both are currently in clinical trials (91, 92).

DAMPS and S100A9
S100A9 is a Danger Associated Molecular Pattern (DAMP) also known as an alarmin.
DAMPs initiate an inflammatory response at its earliest stages. The S100 family consists
of multiple members that exhibit homology to one another. S100A8 (Calgranulin A) /
S100A9 (Calgranulin B) is often found as a heterodimeric complex known as Calprotectin,
however both proteins can be found as homodimers. Neutrophils are the primary
producer of S100A8 and S100A9 to initiate inflammation in many pathogenic states, but
they are also produced by various other cells of myeloid origin (93, 94). In inflammatory
bowel diseases such as ulcerative colitis and Crohn’s disease, the presence of
S100A8/S100A9 complex is a biomarker of disease activity due to leukocyte shedding
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and increased neutrophil presence in the bowel (95, 96). S100A8 and S100A9 are
calcium and zinc binding proteins. Calcium or Zinc are necessary for binding of
S100A8/S100A9 and its ligands (97). Our group has extensively focused on S100A9
biology for the past 10 years, thus Chapter 4 will focus on furthering our knowledge of
the complex molecule that is S100A9.
S100A9 is involved in the migration of myeloid cells and is secreted from these
cells. These myeloid cells are recruited to inflammatory sites and are often found within
the tumor microenvironment (98, 99). Some tumor cell lines themselves produce S100A9
which promotes more inflammation inside the tumor, such as pancreatic, prostate and
colorectal adenocarcinomas (98, 100). The localization of this protein varies between cell
subtypes, in some situations cytoplasmic and secreted, some membrane-bound, but it is
widely expressed, and outside of its overexpression in the context of disease, is a normal
innate immune molecule (101, 102).
S100A9 binds multiple different elements ranging from keratin to Toll-Like
Receptor 4 (TLR4), CD33, and the Receptor for Advanced Glycation Endproducts
(RAGE) which will additionally be the focus of Chapter 4 (60, 98). These multiple
receptors allow S100A9 to signal through different pathways. S100A9 activates Nuclear
Factor Kappa B (NF-κB) signaling which is a pleiotropic signal involved in myriad
biological processes, as well as MAP Kinase (MAPK) signaling (103-105). S100A9 also
leads to the production of multiple cytokines such as IL-6 and IL-1B (106, 107).
S100A9 is involved in a positive feedback loop and acts as a driver of immature
myeloid cells in addition to its function on neutrophils. Many groups have previously
shown that tumors with higher S100A9 have more Myeloid Derived Suppressor Cells
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(MDSC) in inflammatory environments (108-110). Our group uniquely showed that CD33,
a marker for myeloid cells, is a receptor for S100A9 (60).

S100A9 and Myelodysplastic Syndromes
Our group and now others have shown that S100A9 drives the MDS phenotype through
the expansion of MDSC, promotion of pyroptosis, and PD-1 expression in hematopoietic
stem and progenitor cells (HSPC) (60, 70, 111). We have shown that S100A9 is highly
expressed in MDS patient plasma, in particular low risk disease plasma, compared to
healthy donors, as well as the fact that S100A9 is correlated to the expression of somatic
gene mutations (70).
As mentioned above, MDSC are a cell subtype prevalent in many tumor
microenvironments that are the quintessential example of an immature myeloid cell. They
inhibit T cell function and effector immune responses and lead to worse responses in
various cancer subtypes (112, 113). MDS, being a disease of the myeloid compartment,
is often one that has a high percentage of MDSC in the bone marrow microenvironment
when compared to healthy patients (59). These MDSC are Lineage- HLA-DR- CD33+, and
through engagement of CD33 with S100A9, TGFβ and IL-10 are produced, leading to a
suppressed microenvironment. S100A9, as an alarmin, should be a more acute signal
that is rapidly shut off, leading to a break in the inflammatory cascade; However, in this
disease, more S100A9 is present due to more inflammation and leads to more CD33+
cells, which in turn produce more S100A9 (60). This is one mechanism for a lack of
restrained inflammation in the disease.
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Additional work with our collaborators showed that treatment with S100A9
triggered pyroptosis, a form of inflammatory cell death, by inducing active Caspase 1 and
NLR family pyrin domain containing 3 (NLRP3) via a Reactive Oxygen Species (ROS)
dependent mechanism. This was found in both primary MDS samples as well as a mouse
model phenocopying the disease through overexpression of S100A9 (70).
Programmed Death 1 (PD-1) and its ligand Programmed Death Ligand 1 (PD-L1)
is an immune checkpoint that acts a safety switch for T cells during activation. PD-1 is
sharply upregulated after activation, after which point it will come down unless it engages
PD-L1, which can then induce apoptosis. In T cells that have been chronically exposed
to antigen and cytokine, PD-1 may be upregulated and stay at a high expression level. In
the field of tumor immunology, it is often used as a marker of an exhausted T cell (114117). Our group has found that there are less CD4+ and CD8+ T cells in MDS, and that
in both compartments, the percentage of PD-1 is markedly increased compared to healthy
controls. Beyond T cell biology, our group investigated the role of this axis on HSPC and
MDSCs. In MDS patients, we found that PD-1 and PD-L1 are increased on CD71+
erythroid progenitors and CD34+ HSPC, and PD-L1 is increased on MDSC. In vitro
assays with recombinant human S100A9 (rhS100A9) treated healthy bone marrow
mononuclear cells increased PD-L1 on MDSC and PD-1 on HSPC and erythroid
progenitors. Treatment with MDS plasma instead of the recombinant protein showed a
similar effect. Mechanistically, this led to active Caspase 3 and hematopoietic cell death.
Blocking the PD-1/PD-L1 pathway via anti-PD-1 or PD-L1 improved hematopoiesis in a
mouse model overexpressing S100A9, and those cells had increased colony forming
capacity in ex vivo colony formation assays. This signaling is associated with abnormal
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c-Myc activation, as S100A9 treatment was unable to induce PD-1 or PD-L1 in Myc+/mice. Thus, S100A9 leads to c-Myc induction and dysregulation of the PD-1/PD-L1 axis
(111). Overall, S100A9 contributes to ineffective hematopoiesis and pathology in
MDS and other diseases of inflammation, but the adaptive immune compartment is
still not well studied or understood in the disease.

T cells
T lymphocytes are a white blood cell that are an essential component of the adaptive
immune system. They are identified through expression of surface antigen CD3, but
beyond that exist in multiple subtypes (118). Conventional T cells express an Alpha/Beta
(a/b) T Cell Receptor (TCR). T cell development produces a T cell that either expresses
CD4 or CD8 and should have undergone VDJ recombination and have passed through
both central and peripheral tolerance to become a T cell that has unique antigen
specificity and is not autoreactive (119). T cells undergo VDJ recombination when they
are developing in order to gain one single functional unique antigen specificity for which
they recognize. Conventionally speaking, a CD4 T cell is the dominant cytokine producer
and comes in multiple polarizations that depend on the cytokines produced in its given
microenvironment that it is exposed to as a naïve T cell (120). These polarizations are
conventionally termed Th1, Th2, Th17 and Treg. The CD4 subset provides help to other
cells in the immune system through production of cytokines that either drive or suppress
an immune response. Cytotoxic CD4 T cells exist in small percentages and have been
shown to produce Granzyme B, but not Granzyme A (121). The CD8 subset is the
conventional cytotoxic T cell, though they also produce cytokine. T cell effector function
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is similar to that of an NK cell whereby granzyme B and perforin are produced to kill other
cells. These two subsets are typically found at a ratio of 2:1 CD4:CD8 in healthy patients,
and abnormal skewing of this ratio can be indicative of disease (122).
More unique and rare T cell subsets include those T cells with a Gamma/Delta
(g/d) TCR, which range from 1-5% of the peripheral blood and are enriched in certain
tumor microenvironments and epithelial surfaces such as the gut (123, 124). They are
unique in that they kill in a non-MHC restricted manner, but do have a defined TCR
specificity unlike an NK cell (125, 126).
T cell activation is dependent on the T cell’s TCR seeing its cognate antigen
presented to it on an antigen presenting cell (APC) such as a dendritic cell (DC),
macrophage or B cell via MHC. CD4 T cells see MHC Class II, and CD8’s see MHC Class
I. Once this T cell has received a signal through the TCR, costimulation and cytokine are
the other two activation requirements (127). If costimulation is not provided, activation
induced cell death (AICD) can occur mechanistically through a Fas-FasL interaction
(128). Such costimulation is provided to the T cell via the APC cell surface molecules
such as B7.1, B7.1, 4-1BBL, OX40L or CD70, to the cognate T cell surface proteins CD28,
4-1BB, OX40 or CD27 (129, 130). T cells require gamma-chain cytokines such as IL-2, 7, -15 or -21 to function and survive (131). This activation signaling cascade leads to a
chain of intracellular events leading to more cytokine production, proliferation, and
differentiation. When a T cell becomes activated for the first time, the naïve T cell clonally
expands, and at the end of the immune response, the clone contracts into long-lived
memory cells (132, 133).
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The T cell memory phenotype is defined based on chemokines and other receptors
that are dynamic in response to a T cell’s life and localization (131, 133, 134). T cells are
traditionally divided into two categories: effector memory and central memory. The former
of which responds quicker to secondary stimulation, and the latter of which is a longer
lived, but slower responding cell. These can be defined by expression of CD45RA,
CD45RO, CCR7, CD62L, CD27 and others (120, 134, 135). TEMRA T cells are those
memory cells which re-express CD45RA, a marker typically lost upon activation (136).
These cells can either be currently activated or express a more exhausted phenotype,
which can be further discriminated based on expression of CD69 and checkpoint receptor
expression.

Bone Marrow T cells and T cells in Myelodysplastic Syndromes
The bone marrow (as well as the thymus) is a primary lymphoid organ. B cells and T cells
are born here in a process called lymphopoiesis, and the T cells travel to the thymus to
mature. Conventional (a/b) T cells constitute 3-8% of nucleated cells in the human bone
marrow (137, 138). Through signals elicited by chemokines, T cells traffic to the bone
marrow and become resident there, and it is thus known as a home for long-term resident
memory cells (138, 139). Egress of T cells from the bone marrow is governed by G-protein
coupled receptor sphingosine-1-phosphate (S1P) and sphingosine-1-phosphate-1
(S1P1). Gradients of S1P expression allow the T cell to traffic, but CD69, an activation
marker of T cells, suppresses S1P1, preventing T cell egress (140-143). Bone marrow T
cells have been shown to have a higher rate of proliferation, perhaps attributable to
homeostatic proliferation (144).
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T cells in MDS have not been investigated much in terms of their mechanistic
defects. While T cells play an essential role in immunosurveillance in many diseases,
given that MDS is a disease of the myeloid compartment, not much focus is given to the
lymphoid compartment. Typically, the T cells in MDS are not derived from the malignant
clone, but it has been shown in rare cases (145). In MDS BM, a lower CD4 to CD8 ratio
has been found compared to that in healthy BM. Less naïve T cells and more
TEM/TEMRA T cells have also been shown (146). Granzyme and perforin expression
between MDS and healthy bone marrow T cells was not shown to differ (147). T cell
clonality has been shown to be increased in MDS bone marrow, but activation markers
have not been shown to be increased (148). So interestingly, effector memory cells seem
to preside but they do not seem to be activated. In terms of the T regulatory cell
compartment which is of focus due to the frequent comorbidities seen with autoimmune
disease in MDS, low risk MDS patients were found to have more TEM Treg cells, and
they were found to be more suppressive than TCM Treg cells in vitro (61, 62).

Pattern Recognition Receptors and T cells
Pattern Recognition Receptors (PRR) are proteins capable of recognizing structurally
similar motifs or molecules on pathogens or stressed cells in order to initiate an immune
response. PRR’s typically recognize pathogen associated molecular patterns (PAMPs) or
danger associated molecular patterns (DAMPs). Typically, PRR’s are present on innate
cells and the goal is to initiate further inflammatory cues mediated through
PAMPs/DAMPs (149-151). PRR/PAMP/DAMP signaling can induce an immune response
through the APC responding to the threat and subsequently activating the T cell.
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Uniquely, though, some adaptive cells also express PRRs which allow them to directly
respond to stress and create their own inflammatory cascade (152). The most wellinvestigated PRR family on T cells is the Toll-like Receptor (TLR) family. TLR signaling
activates NF-κB and its target genes when LPS or heat shock proteins are sensed. TLR4
signaling in particular has been investigated in T cells, where it was found to enhance T
cell proliferation and survival in vitro particularly within CD4 T cells (153-156). Another
PRR found to be present on T cells is the Receptor For Advanced Glycation Endproducts
(RAGE) (157-160).
RAGE is an immunoglobulin superfamily member PRR that recognizes structural
motifs such as Beta-sheets, amyloid-beta peptides, proteins or lipids that become
glycated (nonenzymatic mediated bonding of a sugar to a protein or lipid) known as
Advanced Glycation Endprodycts (AGEs), S100 family proteins, and HMGB1 (161, 162).
It exists in multiple isoforms including a soluble version that acts as a scavenger, though
most isoforms are typically membrane-bound. RAGE expression has been found on
dendritic cells, granulocytes, monocytes/macrophage, neurons, microglia, muscle cells
and endothelial cells (163). Thus, it is widely express and has multiple roles in
immunobiology and otherwise, where it signals through ERK and NF-κB. This PRR has
been implicated in cellular stress, inflammation, and diseases, typically those of aging
(164, 165). To that end, RAGE has been extensively studied in the fields of skeletal and
neurobiology. It has been found to be a target for therapeutics for Alzheimer’s disease
due to its binding of amyloid-beta, and many compounds have been developed for clinical
trial (FPS-ZM1, TTP448) (166). RAGE ligands have also been shown to signal through
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RAGE in the bone and cause osteoblast apoptosis (167, 168). Importantly, RAGE has
been studied in T cells, but in a limited manner with a focus on diabetes (159).
In terms of basic immunobiology, RAGE has been found to be involved with Th1 T
cell polarization. Th1 polarization is governed by the transcription factor T-Bet, and Th1
polarized T cells are known to produce cytokines IFNγ, TNFα and IL-2. RAGE-/- T cells
were shown to produce more IL-10, IL-5 and TNFα in response to TCR engagement and
costimulation (158). RAGE-/- T cells produced less TNFα and IL-2 compared to wild type
T cells (160). RAGE expression was found to be higher on T cells of patients with
diabetes, likely due to the chronic AGE exposure which is higher in patients with diabetes
(157, 159). Expression of RAGE is shown to increase in these patients after T cell
activation in the CD4 compartment, but is shown to decrease in healthy donors after T
cell activation (157). The RAGE+ T cells in these patients produced more IL-17,
degranulation marker CD107a and IL-5. Transcriptomics showed that the T cells from
these patients that were RAGE+ had higher expression of inflammatory markers and
activation markers(157). Since S100A9 is a ligand for RAGE and is understudied in both
T cells, and unstudied in MDS, this serves the basis for Chapter 4.

17

CHAPTER TWO:
IMMUNE EVASION BY TGFβ -INDUCED miR-183 REPRESSION OF MICA/B
EXPRESSION IN HUMAN LUNG TUMOR CELLS
A note to the reader: this chapter has been previously published in a research article
in Oncoimmunology, Trinh/Kandell et. al. 2018 (169).
Introduction
Lung cancer remains a deadly disease worldwide, due in part to lack of reliable
means for early diagnosis as well as lack of detailed understanding of immune escape
mechanisms developed by the advancing tumor cells (170, 171). Emerging evidence
indicates that microRNAs (miRs) may play a critical role in cancer and could serve as
biomarkers, depending on the tumor type (26). These non-coding small RNAs function
via RNA interference-mediated post-transcriptional gene regulation, and their
dysregulation is of particular importance in cancer development and progression due to
their potency to control genes involved in tumorigenesis, cell cycle control, metabolism,
apoptosis and tumor progression (172). Recently, miR-183 has garnered considerable
attention because of its overexpression in numerous human cancers, including lung
cancer (32, 173, 174). It is part of the highly-conserved miR-183-96-182 cluster, located
on human chromosome 7. In addition to lung cancer, upregulation of miR-183 has been
associated with poor prognosis in carcinomas of the breast (175), colon (176, 177), liver
(178), esophagus (179), prostate (180), and pancreas (181) and is driven by the presence
of a number of promoter elements specific for β-catenin/TCF/LEF-1 in its 5’ UTR (182)
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and thus is associated with cancer development (183). Moreover, tumor-associated
factors such as Transforming Growth Factor-beta (TGFβ) (35) and AKT (184) have been
identified as additional upstream regulators of miR-183 transcription. Additional effects
of mir-183 include the induction of HIF-1α, which has been reported to protect against
hypoxia and starvation (185). Also, miR-183 inhibits apoptosis and promotes proliferation
and invasion by downregulation of Programmed Cell Death 4 (PDCD4) in tumor cells
(178, 179) and is reported to target protein phosphatase 2A (186), EGR1 (187), PTEN
(187) and FoxO1 (188), all of which are involved in tumor cell survival and proliferation.
Although a clear role of miR-183 is emerging as a tumor promoter, it is not known whether
it plays a role in immune escape by the tumor.
In order for a tumor to flourish, it must dampen the immune system and avoid
detection by immune cells, including natural killer (NK) cells. NK cells are poised to kill
aberrant cells, including tumor cells, by virtue of high expression of activating receptors,
such as NKG2D (189, 190). NKG2D is a C-type, lectin-like, type II transmembrane
glycoprotein expressed on activated NK, CD8 T and γδT cells that can recognize ligands
on target cells induced by stress, DNA damage, or cell transformation (191). It utilizes a
specific adaptor protein, DAP10, to signal downstream for mobilization of lytic granules
towards target cells (192). NKG2D recognizes a number of ligands, which include two
members of the major histocompatibility complex class I chain-related (MIC) proteins,
MICA and MICB, as well as 6 members of UL16-binding proteins, ULBPs 1-6 (193-195).
MICA/B constitutes a separate family of highly-glycosylated membrane-anchored MHC
class I-like molecules that share structural homology to the MHC-I heavy chain but does
not bind β-2 microglobulin or transporter-associated with antigen processing (TAP) (193).
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However, this phenomenon is relevant for human NK cells only, as MICA/B are not
conserved in the mouse, unlike Rae1 and ULBP1 (196), (197), so it has not been
investigated in depth in this context. Unlike classical MHC-I molecules, MICA/B proteins
are rarely displayed on normal cells and are only induced upon viral infection, DNA
damage or transformation to serve as danger signals for clearance by NK cells. In fact,
MICA/B has been reported on numerous human cancer types, including lung cancer, and
its level of expression can be prognostic (198-200). Thus, a potent means for transformed
tumor cells to escape immune detection is to downregulate the surface expression of
NKG2D ligands. Despite the ability of NK cells to penetrate the tumor bed, the absence
of NKG2D ligands could blind the NK effector cells to the surrounding tumor cells. To test
this concept, we analyzed whether miR-183 could target NKG2D ligands on tumor cells,
and uncovered a seminal pathway for miR-183 specific suppression of MICA/B ligands
on human lung tumor cells. Therefore, in addition to promoting tumor cell survival and
proliferation, miR-183 has an immunoregulatory property that disarms NK cells by
depleting MICA/B from the tumor cell surface.

Results
MiR-183 is overexpressed and MICA/B is under-expressed in human lung
cancer
Expression of MICA/B can be heterogeneous among tumor types and tumor cell lines
(193, 198). In analysis of MICA/B expression in human non-small cell lung carcinoma
(NSCLC) cell lines, we found low or absent levels of expression on H1155, H1355 and
H2170, H1299, A549 and Wi-38. (Fig. 2A). This was in sharp contrast to human bronchiolar
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epithelial cells, HBE4, transformed by Epstein-Barr E6/7, as well as K562 chronic
myelogenous leukemia cells, both of which express high levels of MICA/B. This data initially
suggested to us that this may be simply a solid tumor phenomenon, however we additionally
analyzed Panc-1 and MiaPaCa and found high levels of MICA/B, similar to that seen on
HBE4, K562, and HeLa (Fig. 3A, 3B). This indicated to us that this is perhaps a novel, lungexclusive phenomenon. Reports have shown that tumor cells can downregulate NKG2D
ligands, including MICA/B, to evade NK and effector CD8+ T cell responses (201-204).
Although MICA/B reportedly can be shed from tumor cell surfaces, downregulation of these
genes is another important mechanism to disrupt MICA/B expression. Emerging data
indicates that miRs are aberrantly expressed by tumors and can control critical genes
associated with proliferation and metastasis. To understand if miRs might also control
immune escape in tumor cells, we focused our efforts on miR-183 which is known to be
overexpressed by tumors of diverse origin, but may be of particular interest in the solid tumor
realm, particularly that of lung cancer, as shown in our previous work (35). Bioinformatics
analysis of the MICA and MICB 3’ UTRs by miRANDA and TargetScan revealed high affinity
miR-183 binding sites in both genes (Fig. 2B), suggesting that both MICA and MICB could
be repressed by miR-183. Of particular interest, no predicted miR-183 binding sites were
present in the 3’UTR of the six ULBPs that are also ligands for the common receptor,
NKG2D, indicating that they are under a separate regulatory machinery than that which
controls MICA/B. We then sought to address whether there was an inverse correlation
between miR-183 and MICA/B expression in the human lung cell lines. Analysis of miR-183
expression among the cell lines revealed that, in contrast to virally-transformed HBE4 cells,
and leukemic K562 cells, which expressed little miR-183, all of the lung lines expressed
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heightened endogenous levels of miR-183 and the level of miR183 expression occurred in
reverse direction of that of MICA/B. (Fig. 2C). Further, analysis of The Cancer Genome
Atlas (TCGA) human lung dataset revealed a striking increase in miR-183 expression in
tumors as compared to normal tissue (Fig. 2D). In contrast, let-7c, a microRNA known to
suppress expression of oncogenes thus leading to cellular proliferation (205), was sharply
downregulated from normal levels in the same lung tissues, as reported by others (206).
The inverse relationship between miR-183 and MICA/B, in combination with the miR-183
binding sites on MICA/B and elevated miR183 expression in the TCGA lung tumor
database, suggested potential MICA/B dysregulation by miR-183 in lung cancer.

Figure 2. Human lung tumor cells express high levels of miR-183 but low levels of MICA/B. (a) Flow cytometric analysis
of MICA/B in human lung tumor cell lines, H1299, H1155 H1355, H2170, A549, and Wi-38, in comparison to EpsteinBarr virus E6/7-transformed HBE4 lung epithelial cells. (b) Alignment of human MICA and MICB 3ʹUTR mRNA and
miR-183 as depicted by the miRanda algorithm (microRNA.org). The number labeling the 5ʹ end of the MICA/B mRNA
represents the nucleotide position downstream of the translation termination codon. Capital letters constitute the miR
seed sequences and vertical lines depict miR binding to mRNA. (c) qPCR analysis of miR-183 in the same lung cell
lines as (A) showed a reverse correlation with MICA/B expression. (d) Using the TCGA database, meta-analysis was
conducted for miR-183 expression in 422 human lung adenocarcinoma (ADC) samples as compared to 46 normal
adjacent tissues, and 332 squamous (SQU) cell carcinoma samples as compared to 45 normal adjacent tissues. Unlike
let-7 miR, which is known to be downregulated in lung cancer, miR-183 was elevated.
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Figure 3. MICA/B surface expression on non-lung human cell lines is higher than that of lung cancers. (A) Human
pancreatic adenocarcinoma tumor cell lines MiaPaCa and PANC-1 express high levels of MICA/B compared to isotype
control. (B) HeLa cervical epithelial and K562 chronic myelogenous leukemia cells express moderate-to-high levels of
MICA/B.

To confirm clinically that elevated miR-183 in the TCGA database correlated with low to
absent expression of MICA/B in lung cancer, we next evaluated surface expression of
MICA/B in paraffin-embedded lung tumor tissues containing adenocarcinoma and
squamous NSCLC. The Allred scoring system was used and a representative figure of
Scores 0-3 is shown in Fig. 4A, as well as non-neoplastic lung parenchyma in Fig. 4B.
(207).

Using this representative data, we see that immunohistochemical analysis

demonstrates that the intensity of MICA/B staining in Grade 1, Grade 2 and Grade 3
squamous cell carcinoma specimens is no different from that seen in normal adjacent
tissue. All tumor grades have approximately the same staining intensity for both
squamous cell and adenocarcinomas. (Fig. 4C). In addition, the percentage of MICApositive tumor cells was not higher than that of adjacent normal tissues, using the Allred
scoring system of 1 = 1/100, 2= 1/10, 3 = 1/3, 4 = 2/3, 5 = >2/3 (Fig. 4D). In
adenocarcinoma specimens, again the intensity of MICA/B staining in all the grades was
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minor (Score 2) similar to that of adjacent normal tissues. Despite this, there exists a
higher percentage of tumor cells expressing MICA/B (Fig. 4E, 4F), which correlates with
earlier Grades 1-2, but not Grade 3. Thus, MICA/B expression is minor, and is not
overexpressed beyond normal levels in lung cancer tissues. We earlier conducted metaanalysis of MICA and MICB mRNA gene expression in patient lung adenocarcinoma and
normal tissues taken from data in a published report (208) and also found little MICA/B
gene expression in the tumors, equivalent to the levels seen in normal tissues (35). Thus,
similar to the low levels of MICA/B seen in lung cell lines, primary patient lung cancer
tissues do not express MICA/B transcripts or proteins beyond the levels seen in adjacent
normal tissues.

Figure 4. Immunohistochemical analysis of MICA/B expression in human lung tumor tissues. (a, b) Paraffin-embedded
adenocarcinoma and squamous cell carcinoma tissues were stained with anti-MICA/B and scored 0–3 using the Allred
Intensity scoring system. In figure 2A, tumor with different IHC scores are represented. In figure 2B, the adjacent non
neoplastic lung parenchyma is represented with macrophages containing carbon deposits. (c, d) Staining Intensity and
+
percentage of MICA/B positive tumor cells in squamous cell carcinoma, using the Allred Percentage scoring system
+
of 1 = 1/100, 2 = 1/10, 3 = 1/3, 4 = 2/3, 5 = >2/3. (e, f) Staining Intensity and percentage of MICA/B positive tumor cells
in adenocarcinoma. ns: not significant, *p < 0.05, **p < 0.001, ****p < 0.0001.
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miR-183 targets MICA in lung tumor cells
To validate the putative miR-183 binding sites on wildtype (WT) MICA/B, we
generated luciferase reporter constructs containing either the MICA 3’UTR or the MICB
3’UTR. We also mutated the 6-8 nucleotide seed sequence in the 3’UTR of MICA
complementary to miR183, which is required for effective transcriptional repression (Fig.
5A). Co-transduction of 293 cells with MICA-WT and miR-183 markedly reduced
luciferase expression, as compared to MICA-WT together with scrambled control
transduction, while mutant MICA-MT, when co-expressed with miR183, resisted
luciferase repression, suggesting that miR183 binding is critical for MICA gene regulation
(Fig. 5B). Similar experiments using MICB were conducted and, while miR-183 could
repress luciferase activity in MICB-WT transfected cells, it could not interfere with
luciferase activity in MICB-mut transfected cells. Thus, both MICA and MICB are subject
to the same control by miR183.
We next verified that miR-183 directly controls MICA/B in lung tumor cells. To
accomplish this, we transfected antisense miR183 into H1355 lung tumor cells to analyze
if loss of miR183 expression could increase MICA/B levels on the transfected tumor cells.
We first confirmed that antisense miR-183 transfection was successful in suppressing
miR-183 expression by qPCR analysis (Fig. 5C). Next, we examined the level of MICA
and MICB expression in these transfected cells by flow cytometry using a monoclonal
antibody that recognizes both MICA/B. MICA/B were significantly upregulated in
antisense miR-183-transfected tumor cells (mean fluorescence intensity (MFI) of 4660)
as compared to scramble control (MFI of 1958) (Fig. 5D, 5E). To ensure that miR-183 is
a common regulator of MICA/B, we also tested another lung cell line, H1299, in a similar
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manner. Expression of antisense miR-183 in H1299 cells markedly increased MICA/B
levels (MFI of 8263) in comparison to scramble (MFI of 3997) and upregulated MICA
mRNA (Fig. 5F, 5G, 5H). Thus, blockade of miR-183 expression was sufficient to
enhance MICA/B expression in lung tumor cells. Together, the results of the luciferase
reporter constructs in HeLa cells together with the anti-sense miR-183 overexpression in
lung tumor cells indicate that it is a direct effect of miR183 binding to the MICA/B 3’UTR
that regulates its expression.

Figure 5. miR-183 targets the 3ʹUTR of MICA/B mRNA. (a) Schematic of luciferase reporter constructs carrying wildtype (WT) MICA or MICB 3ʹUTR as well as mutated (MUT) MICA or MICB 3ʹUTR. The miR seed sequences are depicted
as capital letters and the mutated nucleotides are in red. CMV, cytomegalovirus promoter; LUC, luciferase. (b) 293T
cells were transfected with luciferase constructs containing MICA-WT, MICA-MUT, MICB-WT or MICB-MUT (500ng),
renilla luciferase (5ng) together with miR-183 (25nM). After 24 h, the cells were lysed and quantified for firefly luciferase
activity. (c) Lentiviral constructs containing scramble control or anti-sense miR-183 were transfected into H1355 lung
tumor cells. qPCR analysis was conducted to confirm the downregulation of miR-183 expression by antisense miR-183
(d, e) Flow cytometric analysis using a monoclonal antibody that detects a common sequence in MICA and MICB
indicated that antisense miR-183 transfected H1355 tumor cells upregulated MICA/B expression. D is a representative
staining of MICA/B. (f, g, h) H1299 lung tumor cells also transfected with antisense miR-183 showed upregulation of
both MICA mRNA by qPCR and protein by flow cytometry analysis. G, H is a representative staining of MICA/B. Each
of the experiments is representative of at least 3 experiments performed.
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TGFβ drives miR183 expression to downregulate MICA/B
We had earlier documented that TGFβ was highly elevated in lung tumor cell lines
as well as primary lung tumor tissues (35). In fact, we reported the novel observation that
TGFβ can induce miR-183 from NK cells leading to the loss of a critical adaptor protein
required in mediating tumor lysis. This is highly relevant to all aspects of cancer
immunology and immunotherapy, as NK cells are critical to antitumor immunity. Since we
showed that the exposure of TGFβ reduces the effectiveness of NK cells , which induces
mir-183 and thus suppresses NK cells, we felt that this topic deserved more attention.
Relevant to our past work and thus current study, TGFβ has additionally been reported
by others to downregulate NKG2D ligands (204). Based on the conclusions of the above
cited works, and the knowledge that TGFβ is elevated in lung cell lines, we thus
endeavored to explore whether TGFβ was involved in inducing miR-183 expression in
the tumor cell themselves, consequently leading to suppression of MICA/B. The novelty
of this concept lies in the ability of the lung cancer cells to contribute to tumor induced
immune suppression. Thus, to pursue this exciting concept, we transfected H1355 lung
tumor cells with shRNA TGFβ or scramble control shRNA prior to analysis of miR-183
and MICA/B expression. We first confirmed that TGFβ mRNA was effectively knocked
down by shRNA TGFβ transfection, as compared to the scramble control (Fig. 6A). Loss
of TGFβ resulted in a corresponding reduction in miR-183 expression (Fig. 6B). In
contrast, TGFβ depletion led to increased MICA/B expression, with MFI rising from 659
in scramble control-shRNA transfected cells to 1077 in the shRNA TGFβ-transfected cells
(Fig. 6C, 6D). We reproduced similar results in H1299 lung tumor cells. Depletion of TGFβ
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with specific shRNA (Fig. 6E) also caused significant depletion of miR-183 in H1299 cells
(Fig. 6F), accompanied by an upregulation of MICA/B (Fig. 6G, 6H). Since lentiviral
transfection can induce a type I interferon response, we utilized a pan-Type I Interferon
neutralizing antibody (209) to ensure that our observed biologic effects were due to the
silencing of TGFβ, and not to secondary viral transfection effects or type I interferon itself.
The results were consistent with that of the original experiment, where the loss of TGFβ
led to increased MICA/B expression by flow cytometry the H1299 cell line(Fig. 7B, 7C).
Thus, TGFβ appears to induce miR-183 which can bind the 3’UTR of MICA/B to disrupt
its expression, and this phenomenon is not Type I interferon dependent.

Figure 6. TGFβ suppresses MICA/B expression via miR-183. (A, B) H1355 tumor cells were transfected with antisense
TGFβ or scramble control prior to analysis of TGFβ mRNA or miR-183 by qPCR. Reduced TGFβ expression correlated
with reduced miR-183 expression in these cells. (C, D) In these same cells, flow cytometric analysis and the mean
fluorescence intensity indicated that antisense TGFβ-transfected cells expressed higher levels of MICA/B than
scramble control. C, D is a representative staining of MICA/B. (E, F, G, H) The experiments in H1355 tumor cells were
repeated in H1299 tumor cells and confirmed that antisense TGFβ transfection reduces TGFβ mRNA with a
corresponding downregulation of miR-183, accompanied by heightened expression of MICA/B in tumor cells. G, H is a
representative staining of MICA/B. Each of the experiments is representative of at least 3 experiments performed.
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Figure 7. TGFβ suppresses MICA/B expression via miR-183 in the absence of Type I interferon. H1299 tumor cells
were transfected with antisense TGFβ or scramble control prior to experimentation. Analysis of TGFβ mRNA was
performed via qPCR on the transfected cell lines. In these same cells, MICA/B was analyzed via flow cytometry. The
TGFβ mRNA was decreased in the antisense TGFβ transfected cell lines (A), and the MFI of MICA/B was increased in
the TGFβ knockdown (B, C). The cells were treated with IFN blocking antibody for 30 minutes prior to analysis. Each
of the experiments is representative of at least 3 experiments performed.

miR-183 expression blocks NKG2D-mediated lysis of tumor cells
To analyze the biological consequence of miR-183 expression in tumor cells, we
next assessed the sensitivity of lung tumor cells to NKG2D-mediated lysis by cytotoxic
immune cells. First, we assessed the MHC class I expression of tumor cell lines, as MHC
class I presence is important for NK response. We examined healthy peripheral blood
mononuclear cells (PBMC) as a positive control, K562 immortalized myologenous
leukemic cells as a negative control, and H1299 and H1355 lung tumor cells. We found
moderate expression in H1355, and higher expression in H1299 cells (Fig. 8). These cell
lines are thus class I competent, a factor that is prominent because lung tumor cells often
lose class I expression as a mechanism of tumor immune escape (210). NK cells sense
and detect MHC Class I, and through the missing-self hypothesis, recognize and
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eliminate cells missing Class I(211). NK cells, however, cannot be used as effector cells
to study NKG2D-specific lytic events, because IL-2 used to culture human NK cells
induces not only high levels of NKG2D but also upregulated other activating NK receptors
such as activating Killer Immune Receptors (aKIRs) (212), NKp44 (213), NKG2C (214),
and NKG2E (215), which recognize tumor-associated ligands unrelated to MICA/B. To
overcome this obstacle, we generated cytotoxic CD8+ T cells by first purifying CD8+ T
cells via negative selection from normal peripheral blood mononuclear cells and then
placing them in culture for 7 days with anti-CD3/CD28 containing medium plus IFNγ. We
demonstrated that such short term stimulation induces primarily NKG2D but no other
activating receptors, including NKp44, NKp46, KIR2DS4, or NKG2C (Fig. 9A). Indeed,
these CD8+ T cells lysed H1355 lung tumor cells which could be effectively blocked by
anti-NKG2D (Fig. 9B). The T cell receptor on CD8+ T cells is not involved because H1355
tumor cells are allogeneic to the T effector cells and have no matching MHC-Class I (216).
We next transfected antisense miR-183 into H1355 tumor cells and tested their
susceptibility to lysis by CD8+ T cells. In 2 separate normal donors, we found that CD8+
T cells had markedly increased tumoricidal activity against H1355 mir-183 transfected
tumor cells, as compared to scramble control (Fig. 9D, 9E). To prove that this relationship
between mir-183 and MICA/B sensitizes effector cells, we transfected H1299 and H1355
tumor cells with a vector to overexpress MICA/B. As expected, the tumor lysis phenotype
was similar (Fig. 9C). The CD8+ T cells had a similar trend in tumoricidal acitivity as did
the antisense miR-183 transfected cells. This confirms that this relationship does indeed
work both ways. Taken together, these results indicate that miR-183 suppression, either
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by means of silencing mir-183 or overexpressing MICA/B in tumor cells sensitizes them
to be better recognized by T cells via the NKG2D-MICA/B pathway.

Figure 8. MHC Class I expression on Tumor Cell lines. Healthy PBMC, leukemic K562 cells, H1299 and H1355 lung
tumor cells were analyzed for class I competence. PBMC were used as a positive control, K562 as negative compared
to isotype control. H1299 have moderate-to-high levels of MHC class I, and H1355 moderate compared to isotype
control.

+

Figure 9. Depletion of miR-183 in tumor cells enhances sensitivity to lysis by activated T cells. (a) CD8 T cells, purified
by negative selection from normal peripheral blood mononuclear cells, were activated with IFNγ and anti-CD3/CD28
and cultured in IL2 for 7 days. Flow cytometric analysis indicated that such short term culture induced only NKG2D but
+
not the other NK receptors on the T cells. (b) Short term-activated CD8 T cells kill H1355 tumor cells in a 5 h Cr release
+
assay, which can be blocked by anti-NKG2D. (c) Short term-activated CD8 T cells were transfected with MICA/B
overexpressing vector or scramble control, and then tested for cytotoxicity against H1299 tumor cells. MICA/B
transfected tumor cells were more susceptible to lysis than scramble control, indicating overexpression of MICA/B in
+
tumor cells increases sensitivity to lysis by activated T cells. (d, e) Short term-activated CD8 T cells from 2 separate
donors were transfected with antisense miR-183 or scramble control, and then tested for cytotoxicity against H1355
tumor cells. Antisense miR-183 transfected tumor cells were more susceptible to T cell lysis than scramble control.
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Discussion
In this study, we provide firm evidence of a novel molecular process that promotes
immune escape in human lung tumor cells. It identifies a new link between TGFβ and
miR-183 that drives repression of a critical NK ligand, MICA/B, causing the loss of
detection by immune cells expressing its receptor, NKG2D. Immunohistochemical
assessment of tissues from lung cancer patients with either adenocarcinoma or
squamous cell carcinoma indicated a lack of MICA/B expression while meta-analysis of
the TGCA database for human lung adenocarcinoma and squamous carcinoma revealed
that both lung tumor types display a high expression of miR-183. In light of the reverse
correlation of MICA/B expression with miR-183, we conducted a search for miR binding
sites in the 3’UTR of both MICA and MICB and identified a 7-mer binding sequence that
tightly complements the mature 22 nucleotide miR-183 in MICA and an even longer 9mer sequence that completely mirrors miR-183 in MICB. Using luciferase reporter
constructs carrying the MICA or MICB 3’UTR, we were able to demonstrate that miR-183
effectively repressed MICA and MICB. Sequence-specific mutation of the binding site on
MICA and MICB further corroborated the requirement of miR-183 in regulating MICA/B in
these reporter constructs. Besides such molecular elucidation of miR-183 binding to the
MICA/B 3’UTR, analysis of the biological process in H1355 lung tumor cells indicated that
antisense miR-183 transduction can upregulate MICA/B expression and sensitize these
cells to lysis by activated allogeneic T cells expressing NKG2D. This process was
reproduced in another lung tumor cell line, H1299. Use of short term activated allogeneic
T cells allowed for the recognition of tumor cells by NKG2D without TCR which is selfMHC Class I specific. It also circumvents the issue posed by activated NK cells which
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express other activating receptors such as aKIRs, NKp30,NKp44, NKG2C that could
mask specific MICA/B-targeted killing (189, 190). We also provide evidence of the role
of TGFβ in initiating the process, by demonstrating that anti-sense TGFβ transfection into
human lung tumor cells can downregulate miR-183 expression, with corresponding
increase in MICA/B expression.
Earlier studies have reported that MICA can be controlled by several other miRs,
namely miR-10, miR-20, miR-93, miR-106, miR-373, miR-520 (217, 218) . However,
these miRs were uncovered through the TargetSCAN algorithm to search for miR
consensus sites on the 3’UTR of the MICA/B gene and are not linked to the tumor
microenvironment. It is not known if any of these miRs are inducible by TGFβ, as we have
shown for miR-183 expression in our lung tumor system. One interesting observation
pertaining to MICA regulation is the report that IFNγ can repress MICA via miR-520 (219).
Thus, these other miRs may respond to signals unrelated to TGFβ. Shedding of MICA/B
is another process utilized by tumor cells but it is still not settled whether shed MICA/B
blocks or enhances NKG2D-mediated NK lysis (201-203). This shedding phenomenon
could explain our consistent observation of better detection of cytoplasmic MICA/B by
western blot analysis than by flow cytometric analysis of surface MICA/B.
One of the hallmarks of cancer is immune escape (171). Our work constitutes the
first report of a tumor-promoting miR, namely miR-183, which can also drive immune
escape of tumor cells. In addition to numerous reports of the ability of miR-183 to enhance
tumor progression via direct interference with key regulators of cell survival and
proliferation, we show here that miR-183 expressed within lung tumor cells can repress
MICA/B expression to avoid detection by NKG2D+ CD8+ T cells. This dual effect of miR33

183 on tumor cells can be a powerful driver of tumor cell progression. Remarkably, there
is a third property of miR-183 that we have recently uncovered. Rather than a direct effect
on tumor cells, we reported that TGFβ-inducible miR-183 can repress NK cells within the
tumor microenvironment. Here, miR-183 targets a separate NK lytic mechanism unrelated
to the MICA/B/NKG2D ligand/receptor system. In this case, the ligation of TGFβ
transcriptionally induces miR-183 in NK cells, and it is this NK-associated miR-183 that
specifically represses DAP12, a vital adaptor protein, required to anchor numerous NK
activating receptors on the cell surface, including activatory Killer Immune Receptors
(KIRs) (212), NKp44 (213), NKG2C (214), and NKG2E (215). It is to be noted that the
ligands for these receptors are entirely different from MICA/B and ULBPs1-6. Activatory
KIRs specifically target classical MHC-I molecules, thus facilitating the recognition of
allogeneic tumor cells, useful in bone marrow transplantation in the allogeneic setting
(220). NKG2C and NKG2E primarily recognize HLA-E, which belongs to the MHC-I heavy
chain family, but bind a restricted subset of peptides derived from the leader peptides of
other MHC-I molecules (221). HLA-E is often overexpressed in malignant cells, rendering
them sensitive to NK lysis (222). The ligand for NKp44 is unclear, although viral
hemagglutinin and heparin derivatives have been reported to bind NKp44 (223) (224).
However, anti-NKp44 can dampen NK lysis of various tumor types, suggesting a putative
common ligand expressed on tumor cells. MiR-183 repression of DAP12 can thus have
a potent effect on NK cells, suppressing a variety of activating receptors to essentially
blind them to the tumor cells.
The lesson learnt from our studies of miR-183 on immune modulation, together
with other reports on tumor cell proliferation and metastasis, is profound. The tumor cell,
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working through TGFβ, is endowed with a powerful transcriptional regulator in miR-183
with three essential subversive properties. First, miR-183 can target endogenous genes
to favor aggressive growth. Second, it can dial down NK ligands, such as MICA/B, to
avoid immune detection by a highly potent NK receptor, NKG2D, that is expressed on
both activated NK and CD8+ T cells. NKG2D is also present on γδT cells which infiltrate
a number of human solid cancers (225). Third, miR-183 can not only modulate the tumor
itself to hide from the immune system, it can also disarm the surrounding NK cells by
targeting yet another NK recognition system through repression of DAP12 that anchors
multiple NK receptors, including KIRs, NKp44, NKG2C and NKG2E. It is notable that
tumor cells have evolved to regulate only DAP12 in NK cells instead of its associated NK
receptors, leaving them intact but cloistered in the cytoplasm, representing an economic
means to silence NK cells. In the context of the NKG2D receptor, tumor cells opted to
utilize miR-183 to repress its ligands, MICA/B. Tumor-associated miR-183 thus
represents a global strategy by the tumor to disable immune recognition by innate
immune receptors and simultaneously promote tumor growth. Whether this TGFβ/miR183 network is operative in other tumor types has not yet been explored but it seems
possible that it is a common strategy of most tumor cells, given the abundance of reports
on TGFβ and miR-183 co-expression in breast, colorectal, hepatic, pancreatic and
prostate cancer.
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Materials and methods
Cell culture and reagents
H1299, H1355, H1155, A549, and H2170 human lung tumor cells were maintained in
10% (vol/vol) FBS, RPMI (Thermo Fisher Scientific) supplemented with 1% Pen/Strep,
1% L-glutamine (Thermo Fisher Scientific), and 1% MEM Non-Essential Amino Acids
Solution (NEAA) (Corning). HBE4 human lung epithelial cells transformed with E6/E7 of
the Epstein-Barr virus (American Type Culture Collection) were maintained in 10%
(vol/vol) FBS Keratinocyte SFM supplemented with cholera toxin (CTX 10 ng/mL), bovine
pituitary extract (50 ng/ml), and epidermal growth factor (5 ng/ml). MiaPaCa and PANC1 human pancreatic ductal adenocarcinoma cell lines (American Type Culture Collection),
Wi-38 human lung cells, HeLa human cervical adenocarcinoma cells, and K562 human
chronic myelogenous leukemia cells were maintained in were maintained in 10% (vol/vol)
FBS, Dulbecco’s Modified Eagle’s Medium (DMEM) (Thermo Fisher Scientific)
supplemented with 1% Pen/Strep, 1% L-glutamine (Thermo Fisher Scientific), and 1%
MEM Non-Essential Amino Acids Solution (NEAA) (Corning).

Primary cytotoxic T lymphocytes (CTLs) were obtained from peripheral blood of healthy
donors from OneBlood. CD8+ T cells were purified from peripheral blood mononuclear
cells by negative selection (CD8+ T cell Isolation Kit; Miltenyi Biotech). Purifications
yielded >95% CD8+CD3+ cells by FACS analysis. Cells were then incubated overnight at
37ºC in culture media supplemented with 10% FBS RPMI (Thermo Fisher Scientific), 1%
NEAA (Corning), 1% Sodium Pyruvate (NaPyr) (Corning), 1% Pen/Strep, 1% L-glutamine
(Thermo Fisher Scientific), MycoZap-PR reagent (Lonza), and IFNγ (1000 units/ml),
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followed by activation with anti-CD3/anti-CD28 and expansion in recombinant human IL2 (100 U/mL) for 6 days.

Flow cytometry analysis
For analysis of surface receptors, 1 × 106 cells of each cell line were stained with 5 µl
anti-human PE-conjugated antibody to MICA/B (eBioscience; clone 6D4) or 2.5 uL PEconjugated antibody to HLA-ABC (BD: Clone W6/32). Following incubation with antiMICA/B antibody or anti-HLA-ABC, cells were washed and resuspended in FACS buffer
(1X PBS containing 2% BSA and 0.1% sodium azide) and acquired on a LSR II Flow
Cytometer (BD Biosciences). Primary CTLs were stained with the following antibodies:
CD8-FITC (BD Pharmingen; clone SK1), CD3-PE (Biolegend; clone SK7), NKp44-APC
(R&D Systems; clone 253415), NKp46-APC (BD Pharmingen; clone 9-E2), KIR2DS4APC (R&D Systems; clone 179315), NKG2C-APC (R&D Systems; clone 134591), and
NKG2D-APC (BD Pharmingen; clone 1D11). Data were analyzed using FlowJo version
10 and figures were prepared in GraphPad Prism 7.

Type I interferon neutralization
For neutralizing of Type I interferon, cells were treated with Human Type 1 Interferon
Neutralizing Antibody (PBL Assay Science) for 30 minutes at a concentration of 1:50.
After incubation at 37ºC, cells were harvested and washed, and used for further
downstream assays. Data were analyzed, and figures were prepared in GraphPad Prism
7.
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Chromium release assay
Chromium release assay was performed as described.17 Anti-sense miR-183 lentiviral
transduced H1299 or H1355 cells were used at targets. Targets were labeled with 200µCi
of Na [51Cr] chromate (Amersham) for 1 hr at 37°C. Target cells were then washed and
plated at 5 × 103 cells/well with CD8+ T cells to give an effector/target ratio of 50/1 to 6/1
in a round bottom microtiter plate. After incubation at 37ºC for 5 hr, supernatants were
harvested and counted in a γ-counter. The percent specific

51

Cr release was then

calculated as: [(experimental cpm – spontaneous cpm)/total cpm incorporated] x 100. All
determinations were performed in triplicate, and the SEM of all assays was calculated
typically ~5% of the mean or less. Figures were prepared in GraphPad Prism 7.

Quantitative RT-PCR
To detect mature microRNA (miR) transcripts, PCR was performed with Taqman reagents
(Thermo Fisher Scientific). Purified RNA was reverse transcribed with primer for has-miR183 (miR-183) and RNU6B followed by real-time PCR amplification with 6carboxyfluorescein-conjugated primers for miR-183 and RNU6B in TaqMan Universal
PCR Master Mix, no AmpErase UNG (Thermo Fisher Scientific). Experimental miRs were
normalized to RNU6B. To detect MICA, MICB and TGFβ transcripts, total RNA was
extracted using Trizol Reagent (Thermo Fisher Scientific). Total RNA was then reverse
transcribed using the qScript cDNA Supermix (Quanta). Real-time PCR amplification was
performed with primers specific for the respective mRNA, using the Power SYBR Green
Master Mix (Thermo Fisher Scientific). Relative fold changes in expression were
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determined by using the comparative cycle threshold method (2

−∆∆CT

). Figures were

prepared in GraphPad Prism 7.

Immunohistochemical staining of lung TMAs
Tissue cores (0.6 mm) from 59 adenocarcinoma (ADC), 67 squamous cell carcinoma and
14 normal adjacent human lung tissues purchased from US Biomax were fixed in 10%
(vol/vol) neutral buffered formalin for construction of a tissue microarray (TMA). Sections
of the TMA (4 µm) were stained for MICA/B expression as described using anti-MICA/B
(R&D Systems)17 at a dilution of 1:100, for 2 h at room temperature with the Ventana
automated immunostainer Discovery XT (Ventana Medical Systems, Tucson, AZ). As a
negative control, non-immune mouse sera were used, omitting the MICA/B antibody
during the primary antibody incubation step. The slides were read by a certified
pathologist and co-author (DC) in a blinded fashion and the MICA/B protein expression
levels were measured using the Allred semiquantitative scoring system.41

Bioinformatics analysis of miR binding
Analysis of the MICA (NM_000247) and MICB (NM_005931) 3ʹUTR was performed using
the publically available algorithm miRANDA (microRNA.org) or TargetScan.

Cloning, transfection and luciferase assay
The oligonucleotide containing the MICA or MICB 3ʹ UTR (synthesized by Integrated DNA
Technologies) was amplified by RT-PCR (HotSTar Mastermix, Qiagen). Amplified
products were run on a 1% agarose gel, and extracted using QIAquick Gel Extraction Kit,
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Qiagen) and subcloned into the pMIR-Report luciferase vector (Promega) to generate
either MICA or MICB-luciferase reporter vector. The scrambled miR-183 seed-site
sequence was generated by Mutagenex. The constructs were verified for correct insert
sequence and orientation by DNA sequencing. For luciferase reporter assays, 293 cells
were grown (70% confluent) in 12-well plates and transfected (Lipofectamine 2000;
Thermo Fisher Scientific) with reporter constructs (500 ng per well), renilla luciferase (5 ng
per well), and premiR-precursors (25 nm) (Applied Biosystems). At 24 h later, cells were
lysed, and luciferase activity was quantified (Dual-Luciferase Reporter Assay; Promega)
on a single automatic injection luminometer (Turner Biosystems). Ratios of renilla to firefly
luciferase were quantified, and quadruplicates were averaged; experimental miRs were
normalized to control scramble miRs. Figures were prepared in GraphPad Prism 7.

Lentiviral transfection of cell lines
HIV-based lentiviral expression constructs (purchased from SBI) containing miR-183
(pCDH-CMV-MCS-EF1), antisense miR-183 (pGreenPuro shRNA), or scramble control
were packaged with third-generation packaging plasmids (PMD-g, PMD-Lg, Rev; a kind
gift of Todd Fehniger, Washington University St. Louis) in 293T cells. For TGFβ shRNA,
plasmids (psi-LVRH1GP) were purchased from GeneCopoeia and packaged as
mentioned above. Viral supernatants were harvested, filtered, and concentrated (Lenti-X
concentrator; Clontech). H1355 or H1299 cells (5 × 105 cells per well in a 6-well plate)
were spin-transduced with lentiviral particles at a multiplicity of infection (MOI) of 20 in
RPMI. After two infections, cells were maintained in 10% (vol/vol) FBS RPMI
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supplemented with 1% Pen/Strep, 1% L-glutamine (Thermo Fisher Scientific), and
puromycin to select for transduced cells.

Analysis of published lung cancer datasets
Expression of miR-183 and let7 in human ADC and SQU lung cancer in comparison to
normal tissues were analyzed using the publicly available Cancer Genome Atlas (TCGA)
directories:
LUAD:https://tcgadata.nci.nih.gov/tcgafiles/ftp_auth/distro_ftpusers/anonymous/tumor/lu
ad/cgcc/bcgsc.ca/illuminahiseq_mirnaseq/mirnaseq/bcgsc.ca_LUAD.IlluminaHiSeq_mi
RNASeq.Level_3.1.12.0/
LUSC:https://tcgadata.nci.nih.gov/tcgafiles/ftp_auth/distro_ftpusers/anonymous/tumor/lu
sc/cgcc/bcgsc.ca/illuminahiseq_mirnaseq/mirnaseq/bcgsc.ca_LUSC.IlluminaHiSeq_miR
NASeq.Level_3.1.7.0/.
TCGA IlluminaHiSeq miRNASeq level 3 data were downloaded from the open http
directory of the TCGA data portal. The level 3 (normalized) miRNA quantification data
analyses were utilized: LUAD = 1.12.0, LUSC = 1.7.0. Sample counts were as follows:
LUAD (tumor = 422, normal = 46); LUSC (tumor = 332, normal = 45). Figures were
prepared in R.
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CHAPTER THREE:
MICRORNA-155 GOVERNS SHIP-1 EXPRESSION AND LOCALIZATION IN NK
CELLS AND REGULATES SUBSEQUENT INFILTRATION INTO MURINE AT3
MAMMARY CARCINOMA
A note to the reader: this chapter has been previously published in a research article
in PLoS ONE, Kandell et. al. 2020 (226).
Introduction
Natural Killer (NK) cells are a subset of lymphocytes that produce pro-inflammatory
cytokines such as IFNγ and perforin, and kill target cells through an array of germline
encoded receptors. NK cell activation is a finely tuned balance between positive
(activating) and negative (inhibitory) signals. Ligands for these activating receptors are
found on malignant or virally infected cells, which also frequently downregulate MHC
(227). A robust NK cell response in cancer patients correlates with a positive prognosis
(228, 229), and these clinical data translate to animal studies showing that NK cell
depletion or inactivation increases tumor burden and worsens prognosis (230, 231). This
highlights the important role of NK cells in antitumoral defense. NK are found within tumor
infiltrating lymphocytes (TIL), however they are often rendered dysfunctional by means of
the tumor (24). In the context of disease, NK cells quickly respond to chemokine signals
such as that of the abundantly produced chemoattractant CCL2 (232-234) elicited by
malignant cells or other inflammatory leukocytes, making them early-responders at the
scene of a challenge. While previous studies have shown that CCL2 is required for NK
cell-mediated clearance of viral infections (235), information about NK cell chemotaxis in
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the context of breast tumor challenge is limited compared to T cell trafficking in the
disease, and NK trafficking in other tumor types such as colon (236).
One class of regulators involved in diverse cellular processes are microRNAs (miRs), a
class of small noncoding RNAs that post-transcriptionally represses gene expression by
binding to transcripts exhibiting sequence homology, and inducing transcript degradation
or inhibiting translation (237). Deficiency of Dicer, an RNAse required for functional
miRNA maturation, leads to defective NK cell development, solidifying the importance of
miRNA regulation within NK cells (238). In particular, microRNA-155 (miR-155) is
expressed in NK cells and other leukocytes (239, 240), where it is upregulated by
inflammatory stimuli like Toll-like receptor ligands, IFNβ, TNFα and IFNγ (241), and is
robustly induced in response to activating cytokines IL-12 and IL-18 (242). Several genes
have been identified as functional targets of miR-155, including SH2-containing inositol
polyphosphate 5-phosphatase (SHIP-1) (44), which negatively regulates IFNγ production
in NK cells (242, 243). Additionally, SHIP-1 regulates the actin cytoskeleton at various
levels by interacting with filamin-1, a scaffolding protein that organizes actin filaments in
ruffle formation during chemotaxis (244, 245). Illustrating this relationship, decreases in
filamin-1 or SHIP-2, a SHIP-1-related inositol phosphatase, leads to reduced F-actin
polymerization in response to endothelial growth factor stimulation (246). Furthermore,
SHIP-1 is involved in the regulation of migration of murine neutrophils in response to
chemoattractive agents (247). Taken together, these data support a role for SHIP-1 not
only in the regulation of cytokine secretion, as shown by Trotta et. al. (242) but also cell
motility.
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MiR-155 is processed from the transcript of bic, a non-protein-coding gene (248).
To study the physiological function of bic/miR-155 in NK cells, we utilized the bic/miR155-deficient mouse (miR-155-/-) (242, 248). Previous work has elucidated roles of miR155 in NK cells both in vitro and in vivo, but impairments in chemotaxis are relatively
unexplored. These works have shown that miR-155 is important for NK cell biology in
vivo, showing such defects as impaired Interferon Gamma production and homeostatic
proliferation (45, 49, 242). However NK cells from miR-155-/- mouse spleen displayed
normal frequencies, and displayed a similar percentage of CD94, a marker of
activation.(49). MiR-155 has also been shown to play a significant role in actin
polymerization through the activity of SHIP-1 (242). Given that miR-155 has not been
shown to affect NK cytotoxicity (49), we hypothesized that accelerated tumor growth in
mice may be due to reduced migratory capacity secondary to defects in actin
polymerization in NK cells. To examine this, we isolated NK cells from mice genetically
lacking miR-155, and conducted a series of functional assays, as well as chemotaxis,
transwell assays, and demonstrate that miR-155 may regulate chemotaxis and
subsequent NK tumor infiltration downstream of SHIP-1 in mammary carcinoma.

Results
NK cells in bic/miR-155-/- mice retain normal cytotoxic function
MiR-155 has myriad roles in NK cell functionality, and thus we examined the miR155-/- mouse to interrogate this population. NK cells in these miR-155-/- mice displayed
normal levels of cytotoxicity receptors and frequencies in the spleen when compared to
wildtype, similar to what has been previously characterized (49, 242). Our results were
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similar to the findings cited, whereby the percentage of splenic NK cells was equivalent
in miR-155-/- and WT mice, as assessed by NK1.1/DX5 co-expression (227) (Fig. 10A,
10B), suggesting that miR-155 does not play a role in NK cell development or
homeostasis. NK are typically activated in inflammatory conditions. We thus assessed
the cytotoxic potential of these cells post-activation with IL-2. This cytokine was chosen
as the standard for in vitro NK activation, though other gamma chain cytokines are
sufficient. (249). Splenic NK cells were purified by negative selection, activated with IL-2
(100 U/ml) for 72 h, and assessed for functional phenotype by means of their activating
receptors by flow cytometric analysis and additionally, cytotoxicity towards tumor targets.
To this end, chromium release assay was performed, and similar lytic function towards
YAC-1 murine lymphoma targets, as well as C57BL/6 syngeneic AT3 murine mammary
carcinoma targets were seen in both WT and miR-155-/- derived cells (Fig. 10D). We
found no differences in cell surface expression that might impair cytolytic function, as
miR-155-/- NK cells did not show defects in expression of the activating receptors NKp46,
NKG2D or 2B4 (Fig. 10C). Despite possessing comparable direct lytic function and an
intact activating receptor phenotype, other properties of NK cells equally important for
effective rejection of cancer can be affected by miR-155 deficiency. To follow this further,
were particularly interested in dysregulation of the previously identified miR-155 target,
SHIP-1 (44), as SHIP phosphatase activity negatively regulates NK function.
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-/-

Figure 10. Characterization of miR-155 NK cells. Phenotypic and functional analysis of steady state splenic NK
-/cells. Data shown is representative of 3 experiments performed. A) Spleens of WT or miR155 mice (N=3
spleens/strain) were harvested, pooled, and stained with anti-mouse NK1.1 and DX5. B) Percentage of splenic NK
cells (NK1.1+/DX5+). C) NK Activating Receptor Phenotype was analyzed by flow cytometry using anti-mouse NKp46,
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NKG2D and 2B4. D) Cr-release assay of freshly isolated splenocytes with YAC-1 lymphoma cells and AT3 mammary
carcinoma cells as targets.

miR-155 is linked to SHIP1 and influences chemotaxis
Since SHIP-1 is a defined target of miR-155, and given the previous work on miR155 regulation of SHIP-1 in NK cells (45, 49, 242), we assessed the level of total SHIP-1
in purified NK. Through this, we found that SHIP-1 was upregulated in purified NK cells
of miR-155-/- mice (Fig. 11A, 11B). We additionally performed immunofluorescence on
NK cells isolated from WT or miR-155-/- mice, and found increased cell-surface
localization of SHIP-1 in cells lacking miR-155-/- (Fig. 11C, 11D), suggesting that not only
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is SHIP-1 upregulated, but may be ideally localized to mediate signaling. Collectively, the
data above indicate that miR-155-deficient mice exhibit no defect in direct-lytic NK cell
tumoricidal function, yet express heightened levels of SHIP-1, which is likely to have
consequences on NK functionality.

-/-

Figure 11. miR-155 NK cells overexpress SHIP-1 and do not polymerize actin.
IL-2 activated NK cells were generated from purified splenic wild-type or miR-155-/- NK cells. A) SHIP-1 immunoblot
-/analysis of wild-type (lanes 1-2) or miR-155 (lanes 3-4). IL-2 activated NK cells were derived from four mice per strain.
B) Quantification of the mean ratio of SHIP-1 to actin from densitometry of immunoblots. C) IL-2 activated NK cells
immunostained for SHIP-1. Data shown is a representative of three experiments performed unless otherwise stated.
D) Quantification of mean SHIP-1 membrane intensity from confocal microscopy as in panel C.

In mammalian cells, SHIP-1 is constitutively associated with filamin-1, a scaffolding
protein that organizes polymerized actin filaments into orthogonal angles (244, 245).
Additionally, SHIP-1 negatively regulates phosphoinositide 3-kinase (PI3K) signaling by
hydrolyzing phosphatidylinositol 3,4,5-triphosphate (PiP3), the second messenger of PI3K
that is critical for actin mobilization (250). SHIP-1-mediated hydrolysis of PiP3 results in
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phosphatidylinositol 4,5-triphosphate (PiP2) accumulation. Since PiP3 is required for
events driving ruffle formation and chemotaxis, loss of this phospholipid subsequently
reduces F-actin formation and thus migration (245). SHIP1 has been found to be involved
in all aspects of the NK life cycle (251). With this abundance of information regarding the
relationship between NK cells and SHIP-1, we postulated that the abundance of SHIP-1
could negatively regulate actin polymerization in NK cells. Since polymerization of actin
is required for cellular motility, we reasoned that the chemotaxis to tumor-derived factors
could be affected by miR-155 deficiency. To address this question, we chose chemokine
(C-C motif) ligand 2 (CCL2; also called monocyte chemotactic protein-1 (MCP-1)) as a
chemokine stimulus.

CCL2 is often overproduced in the tumor microenvironment,

including that of breast (252), and attracts T cells, monocytes, and NK cells (235, 253).
Because CCL2 receptor (CCR2) is upregulated on NK cells after activation, we measured
responsiveness to CCL2 chemotaxis after stimulation with IL-2 (232). We compared actin
polymerization in CCL2-stimulated, purified NK cells from miR-155-deficient and WT
animals by phalloidin staining (which detects filamentous (F)-actin) and subsequent
confocal microscopic analysis. In response to CCL2 stimulation, WT NK cells robustly
polymerized actin, as visualized by intense F-actin staining in focal pockets on the surface
of the cells (Fig. 12A). In contrast, CCL2-treated miR-155-/- NK cells did not polymerize
actin as compared to media control (Fig. 12B). Since F-actin polymerization in response
to CCL2 stimulation was defective in those cells lacking miR-155, we hypothesized that
miR-155-deficient NK cells may have a reduced capacity to migrate towards a chemokine
gradient. To address CCL2 chemoattractive capacity, we measured migration of miR155-deficient or WT NK cells towards a CCL2 stimulus in a Boyden chamber chemotaxis
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assay. Using this system, we found that miR-155-deficient NK cells did not migrate
towards a CCL2 stimulus, as did WT NK cells (Fig. 12C). As a confirmation that the
cellular fitness is similar between the NK derived from these mice, a timecourse assay
was performed to evaluate cell viability and marker of NK activation NKp46. The fitness
of the WT and miR-155-/- cells were nearly identical. Viability in at all timepoints under the
influence of CCL2 was ~95% for both groups, and NKp46 expression was unchanged at
all timepoints. (Figs. 13-15). To rule out the possibility that the impaired directional
movement was a result of defective CCL2 receptor density, we examined CCR2
expression amongst the strains. In WT mice, at baseline, there are more NK1.1+ CCR2+
NK cells than those of the 155-/- mice (13.7% vs 5.5%; N=3 mice/strain). However, CCR2
could be induced in both the wildtype and 155-/- NK cells upon stimulation with IL-2, as
has been shown previously (232).(Fig. 12D). Nevertheless, despite comparable receptor
expression post-stimulation, miR-155 deficient NK cells remained unresponsive to CCL2,
suggesting that the impaired chemotaxis may be a result of dysfunctional actin
polymerization. Because SHIP-1 is involved in directional migration and is overexpressed
in miR-155-/- NK cells, we sought to determine whether blocking the function of the
phosphatase could rescue chemotaxis. We utilized the specific small molecule inhibitor
3-α-aminocholestane (3AC) to block SHIP-1 function (254). Inhibition of SHIP-1 activity
indeed rescued the chemotaxis of miR-155-/- cells to a CCL2 stimulus in a dosedependent manner (Fig. 12E).

Collectively, these results suggest that SHIP-1

overexpression resulting from miR-155 deletion confers impaired chemotaxis to CCL2.
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-/-

Figure 12. miR-155 NK cells exhibit an altered response to CCL2.
-/IL-2 activated NK cells were generated from WT or miR-155 purified splenic NK cells. Data shown is a representative
of three experiments unless otherwise stated. A) Representative images of untreated or B) CCL-2-treated IL-2 activated
cells stained with rhodamine-conjugated Phalloidin to detect F-actin. Magnification = 1833.3x; Scale bar = 2 um. C) A
Boyden chamber assay was utilized to detect IL-2 activated cell migration towards a CCL2 stimulus. Data shown is the
absolute number of NK cells migrated toward the stimulus as determined by flow cytometry using CountBrite beads.
D) Naïve or 24-hour IL-2 activated splenocytes were analyzed by flow cytometry for co-expression of NK1.1 and CCR2.
E) Splenocytes were activated with IL-2 for 24h, followed by treatment with the SHIP-1 inhibitor, 3AC. A Boyden
chamber assay was then utilized to detect cell migration towards a CCL2 stimulus. Data shown is the absolute number
of NK cells migrated toward the stimulus as determined by flow cytometry using CountBrite beads. *P < 0.05, **P < 0.01,
***P < 0.005
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Figure 13. Time Course Characterization of C57BL/6 (Wildtype) Derived Splenic NK cells.
NK cell viability over time (Basal, +30 minutes, +60 minutes, + 120 minutes) under the influence of IL-2 and/or CCL-2.
Data shown is representative of 3 experiments performed. Viability was assessed using DAPI.

tm1.1Rsky

-/

Figure 14. Time Course Characterization of B6.Cg-MiR-155
/J (bic/miR-155 ) derived Splenic NK cells.
NK cell viability over time (Basal, +30 minutes, +60 minutes, + 120 minutes) under the influence of IL-2 and/or CCL-2.
Data shown is representative of 3 experiments performed. Viability was assessed using DAPI.
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Figure 15. Time Course Characterization of C57BL/6 (Wildtype) and B6.Cg-MiR-155
/J (bic/miR-155 )
derived Splenic NK cells.
NKp46 expression was assessed over time (Basal, +30 minutes, +60 minutes, + 120 minutes) under the influence of
IL-2 and/or CCL-2. Data shown is representative of 3 experiments performed. Dead cells were excluded via DAPI.
Gating scheme is live, singlets that are TCRB-NK1.1+NKp46+.

miR-155 deficiency confers impaired NK cell tumor tropism in vivo
Since miR-155-deficient NK cells exhibit impaired chemotaxis to CCL2 ex vivo, we
explored the possibility that they would also fail to traffic to a CCL2-rich tumor site. To test
the in vivo relevance of miR-155 in NK cell tumor tropism, we first examined whether AT3
mammary carcinoma cells produce chemokines that induce NK homing.

We

characterized the cytokine and chemokine profile of AT3 cells by using an inflammatory
cytokine cytometric bead array (CBA). As positive or negative controls, cytokine
production from naïve or lipopolysaccharide (LPS)–stimulated C57BL/6 WT splenocytes
was included in the CBA analysis. We found that AT3 produces copious amounts of CCL2
and marginal amounts of IL-6, but not other inflammatory factors such as IFNγ, TNFα, or
the immunosuppressive cytokine IL-10 (Fig. 16A).

After confirming their CCL2

production, we examined the in vivo effect of miR-155 deficiency in rejection of AT3
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tumors by assessing tumor burden and tumor-infiltrating leukocyte composition.
Surprisingly, tumors from miR-155-deficient mice were significantly larger than tumors
from WT mice (Fig. 16B, 16C). Furthermore, hematoxylin and eosin staining of tumor
sections revealed that tumors from miR-155-deficient hosts exhibited a dense lawn of
healthy tumor cells (Fig. 16D). In contrast, areas of tumor tissue necrosis and infiltrating
lymphocytes were present in tumors from WT animals (Fig. 16D). We next isolated
tumors and analyzed the TIL content by flow cytometry. The total leukocyte number was
significantly lower in tumors derived from miR-155-/- background mice (Fig. 17A). The
leukocyte number of splenic derived cells however was not significantly different between
the two strains (Fig. 17B). We next evaluated NK cell, T cell and macrophage presence
by NK1.1, TCR, and F4/80 staining. Unlike that of T cell and macrophage, NK cells were
significantly lower in number in the miR-155 deficient hosts (Tumor-resident NK: miR-155/-

= 4.5% ± 0.9; WT = 11.4% ± 1.3). Splenic NK, T and macrophage numbers were

equivalent. ((Splenic NK: miR-155-/- = 1.8% ± 0.3; WT = 2.0% ± 0.5) (Fig. 4C-D). Our flow
cytometric analysis of these NK cells was confirmed with immunohistochemical staining
of AT3 tumor sections from WT and miR-155-/- hosts for NK1.1+ NK cells.
Immunohistochemistry of AT3 tumor sections from both strains showed noticeably more
NK cells infiltrating AT3 tumors grafted in WT hosts (Fig. 17E). To quantify data from our
immunostained tumor tissues, we scanned tumor sections (N=2 tumors/strain) with
Aperio Scanscope and generated an algorithm in using Definiens TissueStudio Genie
software to determine the percentage of NK1.1+ cells per total nuclei in each tumor
section. Using this system, we indeed observed significantly fewer NK1.1+ cells in tumor
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sections of 155-/- hosts (Fig. 17F). Collectively, these data suggest that miR-155
deficiency confers impaired NK cell tumor tropism in vivo.

-/-

Figure 16. AT3 tumor burden is higher in miR-155 hosts.
A) Supernatants from AT3 tumor cell cultures (black bars), naïve WT splenocytes (stippled bars), or 24-hour LPSstimulated splenocytes (grey bars) were collected and analyzed for cytokine production by CBA. B-D) AT3 tumor cells
-/were injected subcutaneously into the flanks of WT or miR-155 mice. Four weeks after AT3 implantation, the mice
-/were sacrificed and tumors were measured and dissected from surrounding tissues. B) MiR-155 tumor size compared
to WT tumor size. C) Two representative AT3 tumors from each mouse strain with D) corresponding hematoxylin and
eosin stained representative sections. Magnification = 100x; scale bar = 100 um. *P < 0.05, **P < 0.01, ***P < 0.005
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Figure 17. NK cells fail to traffic to AT3 tumors in miR-155 hosts.
-/AT3 tumor cells were injected subcutaneously into WT and miR-155 mice. Four weeks after AT3 tumor implantation,
tumors and spleens were collected and homogenized to single cell suspension for analysis of TILs. Data shown is
representative of three experiments. Percentage of NK cells in the tumor A) or spleen B) of tumor tumor bearing mice
averaged from 3 experiments. C, D) Representative flow cytometric contour plots and graphs of a single experiment
(pooled from 3 mice per strain) showing NKp46+ NK cells in tumor and spleen, as well as TCR+ T cells and F4/80+
-/Macrophage. E) AT3 tumors from WT or miR-155 hosts were fixed, paraffin-embedded and sectioned. The processed
tissues were immunostained with anti-NK1.1 to detect intratumoral NK cells, and images of the whole tissues were
captured with the Aperio scanning microscope. An imaging algorithm was generated to detect the number of NK1.1+
cells in the tumor. Representative areas of AT3 tumors grafted in WT and miR-155-deficient mice and stained with
hematoxylin and anti-NK1.1. Magnification = 200x; Scale bar = 50 um. F) The percentage of NK1.1+ cells in tumors
of WT and miR-155-deficient hosts as determined by an imaging algorithm from 2 tumors per strain. The data shown
report the mean percentage of NK1.1+ cells of the total nuclei count (as determined by hematoxylin stain) of each entire
tumor section. *P < 0.05, **P < 0.01, ***P < 0.005

Discussion
Here, we have shown that miR-155 deficiency in NK cells leads to SHIP-1
overexpression and that this, importantly, leads to faulty chemotaxis in vitro. In vivo, this
results in defective tumor tropism and impaired tumor rejection. In this study, our results
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show that the regulation of tumor infiltration and subsequent NK mediated tumor
clearance and responsiveness is regulated by miR-155. With this study, we provide
exciting evidence that negative regulation of the actin cytoskeleton via SHIP-1 has
consequences in the context of tumor infiltration and cancer rejection. Our results provide
novel evidence of a physiological role for SHIP-1 in NK cell tumor infiltration and implicate
miR-155 in the regulation of NK cell chemotaxis.
miR-155 expression has a myriad of effects on multiple subsets of the immune
system. miR-155 is essential for NK activation, and miR-155 deficiency decreases
interferon gamma production. In terms of other subpopulations, miR-155 along with miR21 have been shown to be involved with MDSC expansion (255), and miR-155 is required
for B cell memory response (256). Additionally, miR-155 deficiency has been shown to
enhance MDSC recruitment thus leading to enhancement of solid tumor growth (257).
This previously published work may indicate potential non-NK reasons as to why the
tumor burden was higher in the miR-155 mice. In the context of T cells which alongside
NK cells are major players in antitumor immunity in the tumor microenvironment, miR155 has been shown to be overexpressed in effector memory T cells, but not naïve or
central memory T cells (48). In the context of viral infection, T cells have been shown to
be defective in the absence of miR-155 (48). Since T cells have been shown to upregulate
miR-155 upon activation and given the expression of miR-155 in effector memory T cells,
miR-155 is thus an essential part of both innate and adaptive immunity. Given that the
bic/miR-155-/- mouse used in our studies is not a conditional knockout within NK cells, but
rather is a whole-body knockout, the T cell response in vivo may be influencing a
substantial amount of the lack of antitumor immunity.
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The gene targets of miR-155 in T cells and NK cells are similar. miR-155 in
particular has been linked to pattern recognition receptor (PRR) pathways in NK cells,
leading to regulation of type I interferon signaling (258). Similarly, in T cells, miR-155 has
been shown to regulate type I interferon signaling, whereby there was increased type I
signaling in miR-155 knockout T cells, and defects in proliferation. Type I interferon
signaling can affect NK cells equally as it can T cells, leading to defects in STAT signaling,
cytokine production, and overall effector function. In terms of Type II Interferons, Banerjee
et. al. showed that in T cells, miR-155 skews T cell differentiation to Th1 by inhibiting
interferon gamma (259). Contributing to this, miR-155 overexpression has also been
shown to increase T-bet expression (260).
This is particularly relevant in the NK cell context given that interferon gamma
production is one of the main ways that NK cells contribute to inflammation and
cytotoxicity in the tumor microenvironment. The T cell response is also one that is slower
to respond than that of NK. Thus, the chromium release assay results may be more
representative of a true innate response, while the in vivo results may be more
representative of what happens to the immune system as a whole over time. While it is
outside of the context of this study, interrogating the T cell compartment in depth in this
model would provide useful – evaluating both T cell memory phenotype and
skewing/polarization.
SHIP-1 is involved in the cytoskeletal remodeling of mammalian cells, via
regulation of the inositol phospholipids PiP2 and PiP3. In WT cells, SHIP-1 expression is
dampened by induction of miR-155. Since miR-155 depletes levels of SHIP-1, PiP3
accumulates at the membrane allowing positive signaling and cellular migration to occur.
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We found that overexpression of SHIP-1 in NK cells resulting from miR-155 deficiency
correlates with decreased motility and abnormal cytoskeletal rearrangement. Thus, miR155-deficient NK cells may have disrupted motility due to overexpressed SHIP-1 resulting
in a lack of PiP3 and abundance of PiP2 at the membrane. A further analysis of the miR155-deficient NK cell cytoskeleton is warranted to determine the signaling proteins
producing PiP3 at the membrane and which actin remodeling proteins are directly
associated with SHIP-1 in NK cells. Furthermore, whether SHIP-1 or PiP3 are directly
involved in actin polymerization in chemotaxing NK cells remains to be determined. Banh
et. al. interrogated the effects of SHIP-1 on NK cell development and maturation and
found that without SHIP-1, NK cells cannot reach the final stage of development and are
functionally immature (43). In the context of our work, we found higher levels of SHIP-1
expression on miR-155-/- cells, with this SHIP-1 expression rendering the NK cells more
dysfunctional. SHIP-1 is important to both development and function of NK cells and plays
different roles in this regard.In our study we did not see impaired cytotoxicity in vitro, but
significant impairments were seen in in vivo models, whereby the tumor burden was
significantly higher and percentage of NK cells in both the tumor and spleen was
decreased in the miR-155-/- mouse. It is important in this study to consider effects of the
tumor microenvironment, which will be highly suppressive to NK cells. This may either
mediated by tumor cell-NK interaction or immune cell-NK interaction (ie. Treg-NK
interaction). In a classical cytotoxicity assay, we perhaps did not see reduced cytotoxicity
in the miR-/- conditions perhaps due to a lack of contextual cues signaling through SHIP1 that may indeed be present in a physiologically relevant environment. A limitation of our
work is the IL-2 activation of the isolated NK cells performed for all of the in vitro assays.
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IL-2 may not be the predominant cytokine in a suppressed tumor microenvironment that
may be skewed more toward a Th2 or suppressive environment driven by IL-10 and TGFβ
(249, 257, 261). Clearly, further interrogation of miR-155 in the context of tumor induced
immune suppression may be warranted.

Materials and Methods
Mice, Cells, and Tumor Challenge
C57BL/6 and B6.Cg-MiR-155tm1.1Rsky/J (bic/miR-155-/-) mice were purchased from
Jackson Laboratory and housed in the Comparative Medicine Facility at the University of
South Florida (USF). All experiments were approved by the Institutional Animal Care and
Use Committee at USF. Mice were evaluated daily, and humanely euthanized via Carbon
Dioxide inhalation. Autoclaved individually ventilated caging (IVC) units (Blueline,
Tecniplast, Buguggiate, Italy) were used for all murine housing. A double-sided rack
configuration with each rack holding 126 microisolation cages (63 cages per rack side)
was used uniformly throughout the murine facility, and each pair of racks was ventilated
and exhausted by a single air handling unit (AHU) trolley. Mice were fed an irradiated
diet (Envigo, Teklad, Diet 2918) and housed on autoclaved pelleted paper bedding
(Envigo, Teklad, 7084). Each cage was provided one nestlet for enrichment (Ancare,
Bellmore, NY).

The AT3 mammary carcinoma line was a gift of Dr. Suzanne Ostrand-Rosenberg
(University of Maryland, Baltimore, Maryland, United States of America).

YAC-1

lymphoma cells were purchased from American Type Culture Collection (ATCC, Virginia,
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United States of America). AT3 and YAC-1 lymphoma cells were cultured in RPMI
supplemented with 10% FBS, 1% Penicillin-Streptomycin, and 1% L-glutamine. For the
AT3 tumor challenge, AT3 cells were resuspended to 1x107 c/ml in PBS. Age and sexmatched mice were injected subcutaneously in the right flank with 1 million cells/mouse,
and tumors were visually monitored daily for four weeks prior to their sacrifice.

NK Cell Isolation
Spleens were harvested from age and sex-matched mice and NK cells were purified with
a NK cell negative selection kit (Miltenyi Biotech; 130-090-864). For each isolation, NK
cells were determined to be >85% pure by NK1.1/DX5 co-expression. Purified NK cells
were cultured in RPMI medium supplemented with 20% FBS, 1% nonessential amino
acids, 1% sodium pyruvate, 1% Penicillin-Streptomycin, and 1% L-glutamine (Gibco). For
production of activated NK cells, purified NK cells were cultured in the aforementioned
media supplemented with 100 U/mL recombinant human IL-2 (Peprotech) for 3 d.

Flow Cytometry
For steady state NK cell analysis, spleens were harvested from age and sex-matched
mice, homogenized to single-cell suspension, and immediately stained with NK1.1-APC
and DX5-FITC (BD Pharmingen; clones PK136, DX5) and 7-AAD (BD Pharmingen). For
receptor phenotyping, 3 d IL-2 activated NK cells were stained with NKp46-FITC, NKG2DPE, or 2B4-APC (eBioscience; clones 29A1.4, A10, eBio244F4) and 7-AAD.

For

determination of CCL2 expression, fresh splenic or 24-hour IL-2 [100 U/ml]-stimulated
splenic cultures were stained with NK1.1-APC, CCR2-FITC (R&D Systems; FAB5538F)
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and 7-AAD. In additional experiments, splenic cultures were stained with NK1.1-FITC,
NKp46 AF647, TCRB PE, and DAPI was used for dead cell exclusion. For TIL isolation
and analysis, spleens and tumors were harvested 4 wk post tumor cell injection. Spleens
were homogenized to a single cell suspension and tumors were strained through 70µm
strainers to a single cell suspension. The homogenized tissues were stained with NK1.1APC, DX5-FITC, and 7-AAD. Samples were acquired on a BD FACSCalibur or BD
FACSCanto II and analyzed with FlowJo software (BD). All data shown is gated on 7AAD-negative events falling within the lymphocyte gate (denoted by Forward vs. Side
Scatter). For detection of cytokines in tumor supernatants, the Mouse Inflammation
Cytometric Bead Assay kit (BD Biosciences; cat#: 552364) was used per manufacturer
instructions.

Chromium Release Assay
A chromium-51 (51Cr)-release assay was performed as described previously (262, 263),
using YAC-1 or AT3 tumor cells as targets for IL-2 activated cells or freshly isolated
splenocytes. Briefly, target tumor cells were labeled with 200 µCi of Na [51Cr] chromate
(Amersham Corp., Arlington Heights, IL) in 0.2 ml of medium at 37°C for 1 h. The cells
were then washed and added to effector cells at 5 × 103cells/ well in triplicate wells of a
96-well round-bottom plate, resulting in various E/T ratios in a final volume of 0.2 ml per
well. After a 5-hour incubation at 37°C, 100 µl of culture supernatants were harvested
and counted in with a γ-counter. The percent specific
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Cr release was determined as

described previously (262, 263) according to the equation: [(experimental cpm −
spontaneous cpm)/total cpm incorporated] × 100. All determinations were done in
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triplicate, and the SEM of all assays was calculated and was typically ~5% of the mean
or less.

Migration assay
Splenocytes from WT or 155-/- mice were incubated for 24 h with IL-2 (100 U/ml) to induce
CCR2 surface expression. The cells were then washed and starved in serum and
cytokine-free RPMI for 4 hours at 37˚C. For inhibition of SHIP-1, the cells were serum
and cytokine starved for three hours and pretreated with 3α-aminocholestane (3AC)
(Millipore; 565835) or ethanol vehicle for the final hour of starvation. The cell suspensions
were then applied to the top wells of a 10-well Boyden chamber, with CCL2-supplemented
[10 ng/ml] RPMI medium in the bottom chamber, separated by a 5-um pore size
polyvinylidine fluoride membrane (Whatman). The apparatus was incubated at 37˚C for
2 h. The migrated cells in the bottom wells were then harvested, resuspended to 500 ul,
and 50 uL Countbright Absolute Counting Beads (Invitrogen; C36960) were added. For
each sample, 20,000 beads were collected. Per manufacturer instruction, the absolute
counts of migrated cells were determined by the following equation: Absolute # cells
migrated = (# of Cell Events acquired on cytometer / 20,000 beads) x (50,000 beads/50
uL).

Western blot analysis
Cell lysates were acquired as previously described (263). Briefly, cells were pelleted and
lysed in 1% NP-40, 10 mM Tris, 140 mM NaCl, 0.1 mM PMSF, 10 mM iodoacetamide, 50
mM Na fluoride, 1 mM EDTA, 0.4 mM Na orthovanadate, 10 µg/ml leupeptin, 10
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µg/pepstatin, and 10 µg/ml aprotinin, followed by centrifugation to remove nuclei and cell
debris. Protein concentrations for each sample were calculated using the Bradford BioRad protein assay. Protein lysates (80 µg/sample) were separated by gel electrophoresis
through a 10% SDS-PAGE gel and were transferred overnight at 20 V/hr to a PVDF
membrane. The membrane was then probed with anti-SHIP-1 (Santa Cruz
Biotechnology; clone P1C1) followed by horseradish peroxidase-conjugated anti-mouseIgG (GE Healthcare Life Sciences). The blot was developed with a SuperSignal West
Femto chemoluminescent reagent (Thermo Scientific). As a protein loading control, the
blot was stripped and reprobed for β-actin.

Immunohistochemistry
Four weeks after tumor implantation, tumors were harvested, bisected, and fixed in 10%
formalin. The tissues were then paraffin-embedded, cut into 5 µm sections and mounted
onto slides. Representative sections were deparaffinized in two changes of xylene,
rehydrated in changes of decreasing ethanol/water solutions, and treated with a citratebased solution (pH 6.0) for antigen retrieval. The tissue samples were then blocked in
1.5% human serum followed by an avidin/biotin blocking kit (Vector Laboratories), and
probed with a biotinylated anti-NK-1.1 (clone PK136, BD Biosciences) overnight at 4ºC.
Slides were then washed and probed with alkaline phosphatase-conjugated streptavidin
(ABC kit; Vectastain) and developed with an avidin/biotin substrate kit (Vector
Laboratories).

The slides were then counterstained with Gill’s Hematoxylin (Vector

Laboratories), dehydrated, and mounted with Cytoseal (Thomas Scientific). The
immunostained tumor tissues were scanned with the Spectrum Aperio Scanscope slide
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scanner, and an algorithm to count immunostained NK1.1+ cells out of total nuclei
(detected by hematoxylin) was generated using Definiens TissueStudio software. The
percent of tumor infiltrating NK cells was determined with the following equation: ((number
NK1.1+ cells/total number of nuclei in tissue)*100). Alternatively, prior to antigen retrieval,
some tumors were stained with Gill’s hematoxylin and eosin, dehydrated, and mounted
with Cytoseal.

Confocal Microscopy
For F-actin staining, IL-2 activated NK cells were serum and cytokine-starved for 4 h. The
cells were then left untreated or treated with 10 ng/ml recombinant mouse CCL2/MCP-1
(R&D Systems) for 30 minutes at 37˚C. The cells were fixed in suspension with Fixation
buffer (BD Biosciences) and 2.5 x 105 cells were cytospun onto microscope slides
(Shandon). The slides were then permeabilized with Permeabilization/Wash buffer (BD
Biosciences) and stained with rhodamine-conjugated Phalloidin (Invitrogen) followed by
mounting with Fluorescent Mounting Media (Vector Labs). The cells were visualized by
confocal microscopy with a 63x oil objective on a Leica TCS SP5 Laser Scanning
Confocal Microscope, and captured images were analyzed with LAS-AF software.
Definiens Tissue Studio version 4.7 was used to analyze the images for green
fluorescence intensity. First a nucleus detection algorithm was applied to the DAPI
channel to segment nuclei based on intensity and size thresholds. Next a simple growth
algorithm of 1 micron was applied to generate a cytoplasm around each nuclei. The
intensity for green fluorescence was measure in each cell, nucleus, and cytoplasm.
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Statistics
Data are presented as means ± standard error of the mean. Differences between
individual groups were analyzed by Student’s t-test using Graphpad Prism version
7.04. P values < 0.05 were considered statistically significant. Significance was also
confirmed with the Wilcoxon rank sum test.
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CHAPTER FOUR:
S100A9 CONTRIBUTES TO T CELL DYSFUNCTION THROUGH ITS INTERACTION
WITH RAGE IN MYELODYSPLASTIC SYNDROMES

Introduction
S100A9 drives the development of Myelodysplastic Syndrome (MDS) through
expansion of Myeloid Derived Suppressor Cells (MDSC) and promotion of pyroptosis(60,
70) (Fig. 18). Despite the identified role of S100A9’s effects on MDSC and hematopoetic
stem and progenitor cells (HSPC), the role of S100A9 on disease progression due to
effects on adaptive immunity are less clear. Here, we report for the first time of the
substantial effects of S100A9 on T cell function in MDS that may lead to greatly impaired
immunoresponsiveness in the disease. Danger Associated Molecular Pattern (DAMP)
S100A9 is a known ligand for the Pattern Recognition Receptor (PRR) Receptor for
Advanced Glycation Endproducts (RAGE) (264). This is the first study to investigate
S100A9’s effects on RAGE in MDS. We endeavored to understand a seeming lack of T
cell response in the disease, and given our work and understanding of S100A9, asked
whether S100A9 would adversely affect T cell function. We identified, through this work,
a mechanism of T cell dysfunction that may lead to a lack of responsiveness in the context
of a disease known to overexpress the RAGE ligand S100A9. Capitalizing on this
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checkpoint can perhaps rescue T cells to a more functional state in the disease by
blocking RAGE.

Figure 18: The Role of S100A9 in Myelodysplastic Syndromes. S100A9 increases MDSC expansion and activation,
which can block T cell functionality. Additionally, S100A9 leads to the production of other proinflammatory cytokines,
as well as induces pyroptosis. Collectively, these lead to impaired tumor immunity, and reduced immune surveillance
through bone marrow hypercellularity and peripheral blood anemia secondary to MDS clone expansion.

Results
T cells from MDS Patients are antigen experienced and functionally normal
We obtained peripheral blood and bone marrow mononuclear cells from MDS
patients as well as those from healthy age-matched controls. We first wanted to
characterize the T cell compartment in the disease in order to determine if the T cells are
functionally and phenotypically normal in this state of pathology. We chose to focus our
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phenotyping predominately on bone marrow mononuclear cells as that is the primary site
of the disease and pathology in MDS. Prior to this, we obtained MDS PBMC to interrogate.
We first examined 3 low-risk (IPSS-0) and 3 intermediate risk (IPSS-3) PBMC’s
from consenting patients. Extensive phenotyping was performed by flow cytometry using
a BD LSR II SORP. When compared to the healthy donors, the MDS patients had less
naïve T cells, and more effector memory, defined by CD45RA and CD62L expression
(Fig. 19A). This is representative of a more antigen experienced state and is expected in
the context of disease. Uniquely, though, while the healthy donors had an even mix of
naïve, central and effector memory T cells, the MDS patients had very few naïve T cells.
This indicates that these T cells in these patients have been activated at some point, but
does not indicate that they are presently activated or not. The low risk patients had more
of a T effector memory re-expressing CD45RA (TEMRA) phenotype, while the
intermediate risk patients had a predominately effector memory phenotype (Fig. 19B19E). The phenotype of the low risk patients may be representative of an exhausted
phenotype, or perhaps more of an activated phenotype. Confirming this with CD69
expression indicates that at rest, the CD8 compartment of the low risk patients is
activated, but this is not seen in the intermediate risk patients (Data not shown). There
may be a shift in memory phenotype or trafficking in response to disease progression in
MDS.
We sought to activate these T cells and found that they are functionally normal in
response to strong stimulation through the TCR and costimulation (anti-CD3/28) + IL-2.
Checkpoint receptors are conventionally studied in the context of an “exhausted” T cell.
Here, we sought to study the checkpoints PD-1, CTLA4, LAG-3, and TIM-3 as markers
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of activation, as they are upregulated sharply after T cell activation. We found that normal
and MDS PBMC all upregulate PD-1, LAG-3 and TIM-3 in response to activation, as well
as CD69 (Fig. 20). This indicates that there may not be a functional defect in these cells
in response to normal activation. This does beg the question as to whether the T cells in
MDS are receiving strong stimulation through their TCR to begin with, but in ex vivo
assays, they do respond well to stimulation.
In order to study the disease more accurately, we interrogated the same
parameters as above with bone marrow. In a previous work by our group, we identified
that there were less CD3% cells in the bone marrow of MDS patient (Fig. 21A). In this
current work, significantly (p<0.001) less T cells (by percent, not absolute number) were
found by flow cytometry, using live, singlet, CD3+s to gate. Within this population,
significantly (p<0.0001) less naïve T cells were found (using CD45RA and CD62L as
above), and significantly (p<0.001) more TEMRA T cells were found (Figs. 21B, 21E).
There was no significant difference between the TCM and TEM populations, though the
trend appears to be an increase in both of these populations (Figs. 21C, 21D). These are
all indicative of an antigen experienced T cell repertoire, similar to that of the blood in
these patients. Unlike the PBMC, the patients did not have a higher expression of CD69,
indicating that in the bone marrow, the T cells did not exhibit an activated profile (Fig.
22E). Similar to the peripheral blood, the BM T cells responded to activation by
upregulating PD-1, LAG-3 and TIM-3 (Figs. 22A-22D). Cytometric Bead Arrays (CBA) for
cytokines associated with Th1, Th2, and Th17 (IL-2, TNFα, IFNγ, IL-4, IL-6, IL-10, IL-17)
cells show that these T cells can be stimulated to produce normal levels of cytokine
compared to their healthy counterparts (Data not shown).
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This data above shows that the T cells in MDS are functionally responsive to
activation, are antigen-experienced, and may not be abnormal as one would expect to
see in a conventional suppressive tumor microenvironment. Given that the disease does
not affect the lymphoid compartment normally, this may be expected, however we felt it
was important to determine what this immunosuppressive microenvironment is doing to
the T cells, since they do not appear to be activated fresh from isolation. Thus, we still
sought to determine what could be possible mechanisms for a lack of responsiveness of
the T cells in the disease.

Figure 19. Phenotypic Characterization of Healthy and MDS PBMC. n=3 healthy, n=2 IPSS-0, n=2 IPSS-3; Gating was
performed utilizing Live, Singlet, CD3+ Cells and defining these memory populations by CD45RA and CD62L. A)
Representative flow staining of Healthy, IPSS-0 and IPSS-3 PBMC samples. B) % of Naïve T cells of CD3+ T cells in
Healthy and MDS PBMC. C) % of Central Memory T cells of CD3+ T cells in Healthy and MDS PBMC. D) % of Effector
Memory T cells of CD3+ T cells in Healthy and MDS PBMC. E) % of T Effector Memory Re-Expressing CD45RA
(TemRA) of CD3+ T cells in Healthy and MDS PBMC.
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Figure 20. Phenotypic Characterization of Healthy and MDS PBMC. n=3 healthy, n=2 IPSS-0, n=2 IPSS-3; T cells
were activated or not with anti-CD3/28 + IL-2 and analyzed by flow cytometry. Upstream gating was performed utilizing
Live, Singlet, CD3+ Cells. A) %PD-1 in CD4+ T cells before and after activation with anti-CD3/28 + IL-2. B) %PD-1 in
CD8+ T cells before and after activation with anti-CD3/28 + IL-2. C) %CD69 in CD4+ T cells before and after activation
with anti-CD3/28 + IL-2. D) %CD69 in CD8+ T cells before and after activation with anti-CD3/28 + IL-2. LAG3(E), TIM3(F), and CTLA-4(G)- Expression before (top panel) and after (bottom panel) activation with anti-CD3/28 + IL-2.

Figure 21. Phenotypic Characterization of Healthy and MDS BMMNC. Upstream gating was performed utilizing Live,
Singlet, CD3+ Cells. A) %T cells within total live cells in HBM vs MDS-BMMNC. B) % of Naïve T cells within CD3+ T
cells in HBM vs MDS-BMMNC. C) % of Central Memory T cells within CD3+ T cells in HBM vs MDS-BMMNC. D) % of
Effector Memory T cells within CD3+ T cells in HBM vs MDS-BMMNC. E) % of T Effector Memory Re-Expressing
CD45RA (TemRA) T cells within CD3+ T cells in HBM vs MDS-BMMNC.
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Figure 22. Phenotypic Characterization of Healthy and MDS BMMNC. Upstream gating was performed utilizing Live,
Singlet, CD3+ Cells. T cells were activated or not with anti-CD3/28 + IL-2 and analyzed by flow cytometry. Black
histograms represent basal, unactivated T cells. Blue histograms represent T cells activated with anti-CD3/28 + IL-2.
Expression of (A) LAG3, (B) CTLA4, (C) PD-1, and (D) TIM-3 within CD3+ T Cells before (black) and after (blue)
activation with anti-CD3/28 + IL-2 for two intermediate-risk and one low-risk MDS patient. E) % of CD69 within CD3+ T
cells in basal HBM and MDS-BMMNC Cells.

S100A9 is a major source of inflammation in the MDS Bone Marrow
Microenvironment and suppresses T cell proliferation
Our group has shown that S100A9 is highly expressed in the plasma of MDS bone
marrow, and in particular in lower risk disease. It drives the production of CD33+ MDSC,
impairing tumor immunity, and contributes to increased rates of apoptosis through its
promotion of pyroptosis via an IL-1B and Caspase-3 mediated mechanism (60, 70, 111).
Since S100A9 promotes inflammation via engagement of multiple immune-related
pathways, we sought to understand what functional effects S100A9 has on T cells. We
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hypothesized that S100A9 activates T cells and promotes a highly inflammatory immune
response. To study the basic science of what effect a DAMP has on T cell biology, we
utilized healthy donor PBMC predominately, as well as MDS BM.
We first chose to interrogate proliferation, as T cells proliferate rapidly after TCR
engagement and cytokine stimuli. Cell trace violet is a lipophilic dye similar in function to
CFSE that is taken up by the parental cell using a conventional flow cytometry staining
method, and the dye is divided evenly between daughter cells. Thus in a conventional
flow plot, the brightest peak is the parental cells, and all the peaks to the left (at dimmer
MFIs) represent the daughter cell divisions. Given the expectation of a PRR to initiate an
immune response, we were shocked to find that PBMC are completely halted in their
division after the first generation of division. Anti-CD3/28 + IL-2 treated PBMC proliferated
normally (Fig. 23A), but those with recombinant human S100A9 (rhS100A9) in the culture
experienced proliferative arrest (Fig. 23B). We confirmed this result in MDS BM, where
the proliferation was arrested in a notable way, but not to the same degree as it was in
PBMC (Fig. 23C). We hypothesized that these MDS BM T cells were already previously
exposed to S100A9, thus the stimuli was not as much of a stressor to the cells as it was
the healthy PBMC, where they wouldn’t have had as much exposure to this DAMP. We
questioned next whether the cells are dying or undergoing apoptosis that would lead to
this halt in proliferation. We found that T cells not activated treated with S100A9 did not
die nor were they undergoing conventional mechanisms of apoptosis as evaluated with
7AAD and Annexin V via flow cytometry (Figs. 24A, 24C). Activated T cells displayed
normal levels of apoptosis upon activation, and this was not increased when treated with
rhS100A9 (Figs. 24B, 24D). This indicates that these cells are healthy, not dying, and not
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undergoing apoptosis and that this is not a mechanism for the decreased proliferative
response. In order to further evaluate potential mechanisms for this, we evaluated the cell
cycle using DNA binding dye 7AAD. This is a mechanism of intracellular staining by flow
cytometry that allows us to visualize the cell cycle. This is a stoichiometric method of
analysis, whereby the cells in S phase will take up more dye than those cells in G1, and
those in G2 will be even brighter. Cells at rest untreated or treated with rhS100A9 did not
display any cell cycle profile as expected due to their lack of proliferation (Figs. 24E,
24G). Those treated with anti-CD3/28 + IL-2 have robust G1, S and G2 peaks (Fig. 24F).
The cells treated with rhS100A9 surprisingly lacked a G2 peak, indicating a G1/S cell
cycle arrest (Fig. 24H). Further analysis with cyclins would confirm this arrest. It is
interesting that the cells were not seen to undergo apoptosis, however it is possible that
they are undergoing repair mechanisms at the snapshot in time that the flow cytometry
assay is capturing.

Figure 23. PBMC and BMMNC proliferation are inhibited by S100A9. Upstream gating was performed utilizing Live,
Singlet, CD3+ Cells. T cells were activated or not with anti-CD3/28 + IL-2, with or without rhS100A9 (5ug/mL) and
analyzed by flow cytometry. Staining was performed with Cell Trace Violet and stimulation was performed for four days.
A) Two healthy PBMC donors activated with anti-CD3/28 + IL-2. B) Two healthy PBMC donors activated with antiCD3/28 + IL-2 and 5ug/mL rhS100A9. C) BMMNC activated with anti-CD3/28 + IL-2 (black) and 5ug/mL rhS100A9
(pink).
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Figure 24. S100A9 does not induce cell death or apoptosis of PBMC but may induce cell cycle arrest. Upstream gating
was performed utilizing Live, Singlet, CD3+ Cells. T cells were activated or not with anti-CD3/28 + IL-2, with or without
rhS100A9 (5ug/mL) and analyzed by flow cytometry. Staining was performed with Annexin V and PI or 7AAD and
stimulation was performed for four days. Apoptosis profile of: A) T cells without stimulation. B) T cells activated with
anti-CD3/28 + IL-2. C) T cells without activation + rhS100A9 (5ug/mL). D) T cells activated with anti-CD3/28 + IL-2 +
rhS100A9 (5ug/mL). Cell cycle profile of: E) T cells without stimulation. F) T cells activated with anti-CD3/28 + IL-2. G)
T cells without activation + rhS100A9 (5ug/mL). H) T cells activated with anti-CD3/28 + IL-2 + rhS100A9 (5ug/mL).

In order to check for functionality of the T cells, we utilized an IFNγ Enzyme Linked
Immunosorbent Assay (ELISA). PBMC treated with anti-CD3/28 + IL-2 produced a robust
amount of IFNγ, and this was significantly halted with rhS100A9 treatment (Fig. 25A). We
then confirmed our results with MDS BM, which were treated with either rhS100A9 or
autologous serum, with S100A9 confirmed by ELISA. The rhS100A9 treatment of
activated T cells led to significantly less IFNγ production, and this was decreased even
further when treated with autologous serum (Figs. 25B, 25C). This indicates that S100A9
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may decrease the T cells functional abilities and outputs in vitro. We hypothesize that the
reason for the autologous serum having a greater effect than the rhS100A9 is simply due
to concentration. We utilize 5ug/mL of rhS100A9 in our assays, which was determined in
a dose curve to be sufficient to suppress T cell responses, but patient serum typically has
much more than this and can be upwards of 20ug/mL (Fig. 25C).

Figure 25: Interferon Gamma production is decreased with S100A9 treatment. A) Healthy Donor PBMC were treated
with 5ug/mL rhS100A9, anti-CD3/28 + IL-2 alone or a combination of the two for four days. B) MDS BMMNC were
activated with anti-CD3/28 + IL-2 with or without 5ug/mL rhS100A9 or autologous serum. C) S100A9 ELISA of
autologous supernatant used to treat the MDS BMMNC.
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In a conventional immune response, there is an inflammatory innate response that
eventually leads to antigen presentation and an activated T cell response and more
inflammation. In all of the assays above, the rhS100A9 treatment was given alongside
the T cell activating conditions. One of the questions that we wanted to evaluate was
whether or not it matters if the T cell is exposed to activation or the rhS100A9 treatment
first. We speculated that the T cell would not be responsive to S100A9 once it was
activated. HBM was utilized here, and IFNγ again as an output. HBM treated with antiCD3/28 + IL-2 a day prior to rhS100A9 treatment produced the most IFNγ, confirming our
thoughts about less sensitivity of the T cell to this signaling once it is already activated.
When S100A9 was provided the day before anti-CD3/28 + IL-2, the result is similar to the
two treatments being provided simultaneously, which is that the IFNγ production is
significantly lower. This indicates that this signaling may be most pertinent to the T cell
only prior to activation (Fig. 26A). CD107a is a LAMP (lysosomal-associated membrane
glycoprotein) that is used as a surrogate for T cell cytotoxicity, as its surface expression
is induced during degranulation. S100A9 treatment the day prior to activation led to the
highest percent of degranulating CD3+ T cells. Those treated with just anti-CD3/28 + IL2 or simultaneous treatment showed 1/3 of the degranulation of those pretreated with
S100A9. Thus the S100A9 may sensitize the T cells to killing (Fig. 26B). A potential
reason for the discrepancy of less IFNγ but more CD107a may be simply a CD4 vs CD8
phenomenon. Though CD8’s produce cytokine, CD4’s are the predominate cytokine
producers in our assays. The larger focus is the degranulation, which is almost exclusively
a CD8 T cell phenomenon. Strikingly, however, we found that the T cells pretreated with
S100A9 displayed a higher percentage of CD4 T cells and that those CD4’s were the
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cells who were predominately degranulating (Fig. 27). We uniquely also found that the
CD4’s preactivated with rhS100A9 displayed the highest percentage of activation marker
CD69 (Fig. 27D).

Figure 26: S100A9 pretreatment sensitizes the T cell to degranulate. A) BMMNC were untreated or treated with antiCD3/28 + IL-2 and 5ug/mL rhS100A9 together, rhS100A9 first followed by anti-CD3/28 post-24 hours, or anti-CD3/28
first followed by rhS100A9 24 hours later for four total days. Supernatant was collected for ELISA. B) PBMC were
activated with anti-CD3/28 + IL-2 with or without S100A9 or S100A9 24 hours prior to anti-CD3/28 treatment. Cells
were collected and stained for CD107a within the CD3+ T cell compartment by flow cytometry four days later.

We next sought to determine how this mechanism of suppression signals. S100A9
is known to signal to NF-κB. Many aspects of the T cell immune response depend on NFκB, including signaling through the TCR, so we performed flow cytometric analysis of
phosphorylation (phosflow) to examine phosphorylated NF-κB p65 (pS529). T cell
activation conditions surprisingly produced a higher % of phospho NF-κB in T cells, and
S100A9 blunted this phospho-NF-κB signaling through the TCR (Fig. 28). This was
another surprising finding, as we expected S100A9 to increase the phosphorylation of
NF-κB, not blunt it. S100A9, while it has been shown to signal through NF-κB, has not
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been shown to signal through NF-κB in T cells specifically. We speculate that there is a
signaling aspect of this DAMP on T cells that is different than its typical signaling on
monocytes.

Figure 27. Schematic of T cell gating for degranulation. From Left to Right: Basal, anti-CD3/28 + IL-2, anti-CD3/28 +
IL-2 + rhS100A9 together, rhS100A9 24 hours prior to anti-CD3/28, and anti-CD3/28 24 hours prior to rhS100A9.
Treatment was performed for a total of four days prior to flow cytometry. From top to bottom: A) CD4 (y-axis) by CD8
(x-axis) within live, singlet, CD3+ T Cells. B) CD107a+ T cells within live, singlet, CD3+ T Cells. C) CD4 (y-axis) by CD8
(x-axis) within live, singlet, CD3+, CD107a+ T Cells. D) CD69+ T cells within live, singlet, CD3+ CD107a+ CD4+ T
Cells. E) CD69+ T cells within live, singlet, CD3+ CD107a+ CD8+ T Cells.
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Figure 28. S100A9 decreases NF-κB phosphorylation through the TCR. T cells from Healthy Donor PBMC were treated
for 15 minutes. A) Graphical representation of flow plots at right. B) PMA, positive control. C) Basal. D) 5ug/mL
rhS100A9. E) anti-CD3/28 + IL-2. F) anti-CD3/28 + IL-2 prior to rhS100A9. G) rhS100A9 prior to anti-CD3/28 + IL-2.

The Receptor for Advanced Glycation Endproducts (RAGE) is expressed on T cells
and is activation responsive
After finding that S100A9 affects T cell proliferation, cytokine production and
degranulation, we inquired as to what S100A9 could be signaling through on the T cell to
mediate its effects. Receptors for S100A9 present on T cells include TLR4 and RAGE.
We did not find robust expression of TLR4 on T cells unlike RAGE, and thus chose to
focus on that receptor. RAGE is associated with inflammatory disease, aging and
hyperglycemia, all characteristics of MDS biology.
We first investigated whether RAGE is expressed on healthy PBMCs and found
that RAGE expression is high (~33%) and sharply decreases at 6 hours of activation with
anti-CD3/28 + IL-2, and continues to decrease (Fig. 29A). RAGE is historically known to
be expressed in the myeloid compartment, but we examined the CD3+ T cell
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compartment and found RAGE to be bright and highly expressed (~50%), and similarly
activation responsive as were total PBMCs (Fig. 29B). We confirmed RAGE expression
by western blot in CD3+ T cells. (Fig. 29C). MDS PBMC displayed a similar phenomenon,
whereby the % of RAGE+ T cells is high at basal levels, and decreased upon activation
(Fig. 30A). Uniquely, though, MDS bone marrow displayed a different phenotype. HBM
displayed low levels T cells that were RAGE positive, and MDS BM displayed consistently
high levels of these RAGE positive T cells, regardless of disease staging (Fig. 30B).
Given that the highest levels of S100A9 are found in the MDS Bone Marrow serum and
comparatively lower levels are found in the MDS Peripheral Blood serum (Data not
shown), this warranted further investigation as a potential mechanism of S100A9’s effects
on T cells in high concentration situations through RAGE.

Figure 29. RAGE is expressed in PBMC and T cells and decreases after T cell activation. Two donor PBMC’s were
activated with anti-CD3/28 + IL-2. Flow for RAGE expression was performed at hour 0 and stimulation was removed at
6 hours. Flow was further performed at 6, 18 and 36 hours post-activation. FMOs are at right. A) Total PBMC. B) CD3+
T cells. C) Western Blot of two donors of basal, CD3+ T cells, blotted for anti-RAGE.
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Figure 30. RAGE is expressed in MDS Patients. A) Donor PBMC were treated with anti-CD3/28 + IL-2 or not and
analyzed for RAGE expression in healthy donor, IPSS-0 and IPSS-3 MDS patients. B)% of CD3+RAGE+ T Cells in
HBM or MDS-BMMNC.

Figure 31. RAGE is restricted to the CD4 T Cell compartment. PBMC or MDS-BMMNC were activated for 6 hours with
anti-CD3/28 + IL-2 for six hours and removed from stimulation. Upstream gating was performed on live, singlet, CD3+
T cells, and in the above, CD4 is on the Y-axis and CD8 on the X-axis. The flow plots are colored by RAGE MFI. A)
Healthy Donor PBMC and B) 3 MDS-BMMNC Donors
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Figure 32. RAGE+ T Cells are Th2 polarized. Transcription factor staining was performed on isolated T cells. Live,
singlet, CD3+ T cells were gated for T-bet, GATA3, RORgT and FOXp3.

Further interrogation of the phenotype of these CD3+ T cells led us to the CD4+
compartment, where the RAGE+ T cells are almost completely restricted (Fig. 31). In
particular, they are restricted to the CD4hi median fluorescent intensity (MFI) cells. This
is the same across patient BM and PBMC from both patient and healthy donor (Fig. 31).
We found through transcription factor analysis of the bone marrow that these T cells are
more of a Th2 polarized CD4 phenotype, expressing the GATA3 transcription factor,
indicating the effects of any cognate RAGE ligand may be limited to the Th2 genetic
program. (Fig. 32).
RAGE+ and RAGE- T cells were sorted from peripheral blood to high purity (Figs.
33A-33C). Performing cell trace violet staining as above led to the finding that the percent
of RAGE+ T cells proliferating under normal activating conditions was higher in the
RAGE+ population, and those RAGE+ T cells responded with a larger decrease in
proliferation when treated with rhS100A9 than their RAGE- counterparts. It is important
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to note that the RAGE- T cells were still suppressed by S100A9, perhaps due to its other
receptors, but it was not to as extreme as a degree as those RAGE+ T cells (Fig. 33D).

Figure 33. RAGE+ T cells are more proliferative and susceptible to S100A9 induced proliferative suppression. T cells
were stained with RAGE-PE and sorted with anti-PE microbeads. A) Pre-sort T cell population. B) RAGE Negative T
cell population. C) Pure Rage Positive T cell population. D) % Divided T cells based on Cell Trace Violet Staining. E)
Unactivated and anti-CD3/28 + IL-2 activated T cells treated or not with 5ug/mL S100A9 for 4 days and analyzed for
RAGE by flow cytometry.

Both RAGE and S100A9 are known to be involved in positive-feedback loops promoting
inflammation. After seeing such high levels of RAGE in MDSBM but not HBM, we asked
whether S100A9 can induce RAGE expression in these T cells. In unactivated T cells,
basal T cells had high RAGE, as did those treated with S100A9. Activated T cells showed
a much-decreased %RAGE+ cells, and this more than doubled when S100A9 was added,
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indicating a positive feedback loop (Fig. 32E). This indicates that these T cells are
responsive to S100A9 treatment by upregulating RAGE which may uniquely allow them
to sense more S100A9, and lead to a decrease in proliferation and inhibition of function
and cytokine production. Knockdown to confirm this has been performed, and we expect
to see reversal of these phenomena in future efforts. Schema below. (Fig. 34)

Figure 34. Schematic for RAGE (AGER) knockdown in T cells. A) Schematic. B) Successful knockdown of AGER gene.

Discussion
Here we show that S100A9, a DAMP that has previously been unstudied in the
context of adaptive immunity, inhibits T cell functionality. This is novel because rather
than a myeloid cell-T cell interaction leading to the suppression of a T cell, it seems the
myeloid produced factor is all the T cell needs to be suppressed enough to not proliferate.
T cells in MDS appear to be normal in terms of their response to strong activation cues
via checkpoint expression of PD-1, CTLA4, LAG-3 and TIM-3, and activation responsive
gene CD69, but they differ in their expression of PRRs. The percentage of T cells is
decreased in the disease and this may be due to apoptosis not induced by S100A9. The
memory phenotype of MDS T cells is less polarized toward naïve and is more represented
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by antigen experienced TCM, TEM and TEMRA T cells. The bone marrow is a home for
long-term memory T cells, so this is partially expected, but also representative of a
diseased phenotype and some sort of antigen experience throughout the T cells life. What
is still unclear is whether the T cells natively have defects in proliferation inside these
patient bone marrows. If antigen presentation is inhibited at all in the disease, then the T
cells may not be able to receive strong stimulation through their TCR to begin with enough
to show defects in proliferation. S100A9 does not induce T cell death in any way or
conventional mechanisms of apoptosis. Interferon gamma is reduced in both healthy and
patient samples with S100A9 indicating that this is potent enough to affect even healthy
non-S100A9 conditioned cells. Preconditioning with S100A9 produces a T cell that
degranulates more, and preconditioning with anti-CD3/28 + IL-2 leads to a T cell
producing more IFNγ. Additionally, S100A9 blunts phospho-NF-κB signaling through the
TCR, and thus it may inhibit NF-κB target genes which are all important in the T cell
immune response and thus this could be a potential mechanism for the inhibition of T cell
function and cytokine production.
RAGE was found to be high on MDS PBMC and HD PBMC. Interestingly, MDS
BM had high levels of RAGE expression, but HBM had much lower expression levels.
The RAGE expression within the CD3+ compartment is restricted to CD4+s, particular
those with the highest CD4 MFI. These CD4s, while not being the conventional cytotoxic
cells, guide the immune response and shape the milieu of the bone marrow
microenvironment through their cytokine production. Thus despite not directly killing the
cancer cells themselves, they are an essential component of the microenvironment and
cannot be overlooked in the disease. They may not fit into a specific lineage, though this
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requires further study, they seem to have more of the transcription factor GATA3,
indicating that they may be Th2 polarized. In the MDS BM microenvironment, this would
be the expected cytokine anyway due to the IL-10, TGFβ driven exposure. We found that
RAGE+ T cells are more proliferative than their RAGE- counterpart, however this may be
due to the fact that RAGE+ T cells are CD4+ which are natively more proliferative than
their CD8 counterparts. What is still difficult to understand is the dynamic RAGE
expression and why it is high in both patient and healthy PBMC but high only in MDS BM
but not HBM. It is reasonable that based on the feedback loop of RAGE expression found
that S100A9 is able to drive RAGE expression, which can explain why MDS BM is higher
in RAGE expression than the healthy counterparts, but this still does not explain what is
occurring in the PBMC. It is possible that the dynamics of innate immunity are different in
different locations, where there are different contextual cues, and the immune cells are
expected to do different things.
It is not completely clear that these S100A9 induced phenomena are mediated
through RAGE, however the convincing positive feedback loop and dynamic expression
indicate that it is a likely binding partner. Previous studies have indicated that RAGE
expression is high on T cells in inflammatory states, and we show for the first time that
RAGE+ T cells are high in the inflammaging-associated disease MDS. What is still
unknown is how this T cell is being shut down mechanistically, if there are different
pathways affected by this S100A9/RAGE axis that are suppressive to the T cell and if
these are altered in the disease or not.
In conclusion, T cells are profoundly affected by S100A9 treatment, and this may
indicate how these T cells are suppressed in MDS. This mechanism of
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immunosuppression offers hope in a disease that despite having many different treatment
options still has poor outcomes. Targeting this axis could potentially lead to reinvigoration
of the T cell compartment in the disease and better survival, leading to prevention of AML
progression.

Materials and methods
Cell culture and reagents
Peripheral Blood Mononuclear Cells were isolated from blood provided by healthy donors
from OneBlood. All patients were recruited from the Malignant Hematology clinic at the
H. Lee Moffitt Cancer Center & Research Institute. After obtaining written informed
consent, patients were classified according to World Health Organization and
International Prognostic Scoring System criteria. Healthy Bone Marrow Mononuclear
Cells were obtained from StemExpress. Samples were diluted 2x using PBS and then
isolated using Ficoll-Hypaque gradient centrifugation according to manufacturers
guidelines. Red cells were lysed using Red Blood Cell Lysis Buffer (Sigma) according to
manufacturers suggestions. Cells were counted and used for downstream assays without
freezing.

T cell activation and culture
T cells were activated with Human T-Activator Dynabeads (anti-CD3/CD28) (Invitrogen)
at a 1:1 ratio. T cells were cultured in X-VIVO 15 Media (Lonza) with 300 IU IL-2
(Peprotech), 5% Human AB Serum (Access Biologicals), and 10% PSG (Gibco) or
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RPMI-1640 (Gibco) with 100 IU Human Interleukin-2, 10% Fetal Bovine Serum and 10%
PSG (Gibco). T cells were treated with 5ug/mL recombinant Human S100A9 (Origene).
In some experiments, fresh, autologous serum was used at 20% v/v. Bone marrow T cells
were subject to Pan-T cell isolation (Miltenyi) according to manufacturers instructions.

Flow cytometry analysis
All antibodies in all assays were pre-titrated prior to use according to best practices in the
field. For analysis of surface receptors, 1e6 of the given sample was stained in a 7.5mm
FACS tube (Falcon) with the pre-titrated concentration of antibody. Cells were washed 2x
with PBS. Live/Dead staining (LD Aqua, LD Blue or LD Near Infrared, Invitrogen) was
performed for 30 minutes at 4 degrees Centigrade, and washed twice with PBS. FC block
was applied to the cells for 10 minutes prior to surface antigen staining. Cells were then
stained with antibody cocktail alongside Brilliant Buffer Plus (BD). Cells were washed 2x
with PBS and resuspended if only staining for surface antigens. For intracellular staining,
cells were fixed and permeabilized using Fixation/Permeabilization Solution Kit (BD
Cytofix/Cytoperm) according to manufacturers instructions. For cytokine staining, cells
were pre-treated for 6-8 hours with Golgistop (BD). Staining was performed using pretitrated antibodes to intracellular antigens. Cells were washed 2-3x with PBS prior to
acquisition on a BD LSR II SORP or BD FACS Symphony. Samples only interrogating
cell surface antigens were ran fresh and not fixed. Transcription factor staining was
performed using the BD Human FoxP3 Buffer Set according to manufacturers
recommendation. Cell Trace Violet (Invitrogen) staining was performed according to
manufacturers recommendation. Compensation was performed either with cells or
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Ultracomp eBeads (Invitrogen). Consistency between experiments was tracked using 8
peak Rainbow Beads (Sphero). Data were analyzed using Flowjo Version 10 (BD) and
graphed using Graphpad Prism Software Version 8. Prior to analysis, all gating upstream
of the populations of interst followed the scheme: LYMPHOCYTES (FSC/SSC) à FSC
SINGLETS (FSCH/FSCA) à SSC SINGLETS (SSCH/SSCA) à LIVE CELLS (SSC BY
VIABILTY DYE).

Interferon Gamma Enzyme Linked Immunosorbent Assay
Interferon Gamma ELISA (R&D) was performed according to manufacturers
instructions. All samples and standards were ran in triplicate. Data were graphed and
analyzed using Graphpad Prism Software Version 8.

Cytometric Bead Array
BD Th1/Th2/Th17 CBA was performed according to manufacturers instructions and
analyzed on a BD LSR II SORP. All samples and standards were ran in duplicate. Data
were analyzed using Flowjo Version 10 (BD) and graphed using Graphpad Prism
Software Version 8.

Western Blot
Cells were lysed using RIPA (Thermo) with protease and phosphatase inhbitors (G
bioscience) on ice for 30 minutes. Cell lysates were centrifuged at 13,000g for 30 minutes
to remove debris. Protein concentration was determined using Bradford assay (Bio-Rad).
30ug of protein per lane was separated on 12% SDS-PAGE gels and subsequently
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transferred using a Semi-Dry transfer to PVDF membranes, which were probed for antiRAGE (Santa Cruz).

Virus Production and Transduction
Short hairpin RNA (shRNA) targeting AGER (Advanced Glycation Endproduct Receptor)
was purchased from Origene. This was packaged in the 293GP2 packaging system with
VSV-G env protein (Takara). The retroviral supernatant was harvested and filtered using
a 0.22um filter. T cells were activated for 48 hours prior to spinfection. The cells were
allowed to rest for 3 days prior to downstream assay. T cells were selected using
Puromycin for 3 days and knockdown was confirmed via western blot.

Statistical Analysis
Data are presented as means ± standard error of the mean. Differences between
individual groups were analyzed by Student’s t-test using Graphpad Prism version
8.3. P values ≤ 0.05 were considered statistically significant, where * represents p values
of ≤ 0.05, ** ≤0.01, and *** ≤0.001. Significance was also confirmed with the Wilcoxon
rank sum test.
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CHAPTER FIVE:
IMPLICATIONS AND FUTURE PERSPECTIVES
Our understanding of the dynamic interplay between cancer and the immune
system has greatly evolved in the past decades. Despite this, it can still be insurmountably
difficult to predict the immune response to tumor. Treatments are changing, personalized
medicine is evolving rapidly, and immunotherapy is coming of age, but there are still
foundational basics that are not understood in terms of mechanisms of tumor induced
immune suppression that lead to either innate failure of the immune system or therapeutic
failure. This work focuses on the former – identifying mechanisms of tumor induced
immune suppression that can lead to better therapeutics and can be capitalized upon for
biomarker analysis in these patients.
Natural Killer cells and T cells are one of the power couples of the immune system,
both providing highly effective effector lytic activities at earlier and later stages in the
immune response, respectively, to any pathogen or transformed cell that dares to cross
them. Unfortunately, they are both equally susceptible to multiple mechanisms of
subversion, be it through checkpoint receptors, cytokines, or in this case, uniquely, miRs
and PRRs.
NK cells, as one of the first lines of the effector response in the immune system
are one of the first affected by these mechanisms employed by the tumor to subvert the
immune response. Early on in the immune response, they are of the first to produce
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interferon gamma and other cytokines in order to shape the subsequent effector response
of the immune system. While NK cells are found within the tumor infiltrating lymphocytes,
they are often those that are lacking in cytokine production and have insufficient
production of lytic granules granzyme B and perforin (24). So, while they are able to
infiltrate into the tumor, they may not be able to perform their effector functions. Due to
their delicate response to a balance of activating and inhibitory signals, they are especially
susceptible to changes in receptor/ligand interactions governed by the tumor. MICA/B, a
NK2DG ligand is upregulated in multiple tumor types as well as more basic occurrences
of cell stress as a mechanism to induce NK cell lytic activity via the MICAB/NKG2D axis
(198-200).
TGFβ

is

highly

overexpressed

in

the

lung

adenocarcinoma

tumor

microenvironment (35). TGFβ has been known for years to suppress NK cell functions,
but its mechanism was largely unexplained until our group discovered that TGFβ reduces
cell surface expression of NK receptors KIR2DS4 and NKp44, and abrogates expression
of critical NK cell adaptor molecule DAP12. Our group found that miR-183 was sufficient
to repress DAP12, but it was not known at this time if any other NK receptors or adaptor
proteins were affected (35). This most current work shows that miR-183 also regulates
NKG2D, making this phenomenon one that is relevant to both NK cell and activated T cell
biology, given the activation responsive increase of NKG2D on both CD8 and
Gamma/Delta T cells as well. MiR dysregulation has been found to affect all tumor types
and most aspects of immunology as well (26, 27). It is worth exploring this pathway in
other tumor types given the expression and dysregulation reported in non-immunology
contexts with the role of the miR-183 family on prostate, breast and pancreatic cancers
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(175, 180, 181). Our work integrates the use of lung cancer cell lines as well as primary
patient samples which are extremely heterogeneous, making this a deeper analysis of
this pathway than just using cell lines alone. This investigation indicates a real possibility
for targeting this pathway for to increase immune surveillance and response in lung
cancer.
Later work led us to study miR-155, which itself is an essential part of the immune
response and is necessary for leukocyte functioning. While miR-155 expression is
upregulated by inflammatory stimuli such as interferon gamma in promotion of an effector
immune response, its expression is culled by conventionally suppressive cytokines like
IL-10 (241, 242, 265, 266).
The first studies of this miR led to a miR-155 knockout mouse, which was
characterized to have dysfunction across the B and T cell compartments (267). This miR
was identified as one that is important in both homeostasis of the immune cell, but also
is induced upon activation and cytokine exposure (45, 49, 242). Of the earliest targets
identified of miR-155 was SHIP-1, and when miR-155 was overexpressed, SHIP-1
expression decreased (45). Since this miR is cytokine responsive, in a tumor
microenvironment which may be dominated by a “cold” environment, NK cells may be
more or less responsive, due to SHIP-1, downstream of inhibitory NK cell signaling.
Interestingly, we and others showed that miR-155 deficiency does not affect NK
cytotoxicity despite being essential for NK cell cytokine production. In previous works, it
was shown that miR-155 deficient mice lack viral-specific NK effector response compared
to wildtype mouse response, and that these mice do not go on to develop NK memory at
the contraction phase of the immune response. Additional targets of miR-155 affecting
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NK cell function include Noxa and SOCS1, which were found to be elevated in miR-155
knockout mice similar to SHIP-1 (49). These results suggest that NK cells require miR155 while resting and while activated, and that miR-155 effects multiple essential gene
regulatory points throughout the life cycle and function of an NK cell. These all confirm
the importance of the tight regulation of miR-155 levels being of the utmost importance
for controlling the NK response not just to tumor, but in response to all threats, viral, tumor
or otherwise. Thus, while these cells display normal cytotoxicity levels compared to
wildtype NK cells in in vitro and in vivo assays, heightened SHIP-1 resulting in suboptimal
antiviral response and a lack of NK memory may represent a form of immune suppression
(49).
The current novelty presented here focuses on impairments in chemotaxis. SHIP1 has been reported to negatively regulate PI3K signaling by hydrolyzing the mediators
necessary for actin mobilization. SHIP-1 leads to loss of these mediators, and thus
directly affects chemotaxis (254). In our work, we found less F-actin at the leading edge
of the NK cells lacking miR-155, indicating impairments in actin polymerization, which is
necessary for chemotaxis. CCL2 is a chemokine that is highly expressed in tumors (252).
In the absence of miR-155, these knockout NK cells had comparable receptor expression
of CCR2, but were not able to traffic into the CCL2+ tumor beds. Of course, trafficking is
never as simple as a single chemokine axis, however it was compelling to see normal
trafficking in the wildtype models. While the CCL2/CCR2 axis was chosen based on its
expression levels in the chosen tumor model, other chemokines may be involved and
affected. We found that blocking SHIP-1 rescued the chemotaxis of these cells, and in
other works this has been shown to increase apoptosis of cancer cells. There are however
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considerable risks with targeting SHIP-1 due to its myriad roles and regulatory processes.
Regardless, SHIP-1 inhibitors 3AC and K190 have been investigated and led to less
efficient immune responses which may be beneficial depending on the disease, but in
other cases lead to activation induced cell death of the tumor cell (254, 268). Like many
things in immunobiology, there exists a goldilocks zone of ideal activation versus
inhibition.

In situations such as hematopoetic malignancy where NK cells are too

inflammatory, miR-155 expression dynamics may represent a unique mechanism by
which NK cells can be shut down, and may be ideal in the bone marrow transplant field
(251, 269). By upregulating SHIP-1, the NK cell is inhibited and is unable to produce
sufficient cytokine to induce an immune response. Overwhelmingly, the key finding is that
miR-155 can directly affect NK cell chemotaxis secondary to defects in actin
polymerization, and that this may be targeted therapeutically, but it may be at the risk of
the NK cell. Through the years, miR-155 has truly come of age as a potent regulator of
both NK cells and T cells, but this represents the first investigating into actin
polymerization and chemotaxis therein.
Therapies to target miR dysregulation are complex and lack extensive in vivo
efficacy and safety testing. It is a well established lab procedure to block miRs in vitro by
using complimentary oligonucleotides, but in vivo mechanisms are still being studied.
Perhaps what is more relevant in the case of the miR-183 story is blocking TGFβ
signaling. TGFβ can be blocked in vivo with small molecule inhibitors or antibodies to
great antitumor effect, which could be relevant in this case and more simple than
attempting to manipulate miRs (270). Regardless, this mechanism of basic immunology
that we found to affect lung cancer has consequences translationally, and will be useful
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for the development of further therapies. Dynamics of cytokine expression control the
miR-155 story more, and thus controlling expression of this miR via cytokine exposure
may be an option, as blocking this miR would not likely prove beneficial.
MDS immunobiology is complex and largely untouched outside of the context of
myeloid cells. This is understandable given the location of the somatic mutations and the
fact that the malignant clone does not often affect the lymphoid compartment. Here we
show that there are mechanisms of T cell suppression that exist outside of the MDSC-T
cell interaction studied almost exclusively in the disease. Our group has shown that
S100A9 is overexpressed in the serum of MDS patients, particularly at the early stages
of the disease (70). Previous work by our collaborators showed that T cells dynamically
change with disease progression. The T regulatory compartment was studied and there
was found to be a change from central memory Treg to effector memory Treg. By this
point the equilibrium phase of immunoediting has past and the myeloblasts have
accumulated to the point of immune escape and Treg expansion (61, 62). Since S100A9
has been seen to be higher in early disease stages but not late, it is possible that this
DAMP affects T cell function at earlier stages, but by the point the disease has progressed
past equilibrium, the S100A9/T cell interaction is a null point. Since one of the most
important things to do is prevent disease progression, this is an exciting mechanism that
is possibly more useful for early-stage disease. The hypothesis that this mechanism of T
cell suppression could be allowing the malignant clone to grow unchecked later in the
disease is compelling, but more work is needed.
Of the most unique findings of this story is the suppression of proliferation by
S100A9. It is still incompletely understood as to why this DAMP, which for all intents
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should promote an immune response, would be shutting down normal responses to T cell
activation. Still, there is consideration that in vivo this may not occur given the number of
positive activating signals a T cell would receive in addition to stimulation through the
TCR, costimulation and cytokine in a healthy person, with a normal immune response.
This does provide basic biologic insight both dependent and independent of activation.
Cancer, however, changes the game in regard to all of these factors. Insight into the
dynamics of T cell dysfunction provided by S100A9 was provided through the
experiments that showed that T cells are sensitized to S100A9 if and only if the S100A9
is provided prior to stimulation through the TCR. It is not clear whether in MDS TCR
stimulation is of sufficient strength to overcome all of the negative stimuli provided such
as S100A9 in this case, especially when there are other immunosuppressive factors at
play such as excessive TGFΒ and IL-10, however these T cells ex vivo from the patients
are absolutely not responsive to S100A9 prior to strong anti-CD3 activation coupled with
cytokine. This is coupled with the unique finding of high levels of degranulation (CD107a+
cells) induced by S100A9 pretreatment only. The genetic programs endowed by S100A9
that lead to increased production of cytotoxic granules, but similarly less interferon
gamma production seem to be at odds with one another, and the importance of further
interrogating the transcriptome of these T cells responding to DAMPs in general cannot
be understated. There are complexities of CD4 T cells that are just being touched upon,
and it is important to think outside of the box in both basic immunobiology and in situations
of this very complex disease.
RAGE expression on T cells is a novelty that has not been extensively explored
outside of the context of diabetes (157-160). This work represents a first of its kind
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exploration into the role of marrow infiltrating lymphocytes being suppressed by factors
that should normally be immune-response promoting. Chapter 4 in particular lays the
foundation for multiple therapies to be capitalized upon. This work has opened the door
to more unanswered questions that include why the RAGE expression is so dynamic
between blood and bone marrow, and whether or not it is enough to be used as a
prognostic marker in the disease. RAGE inhibitors are being utilized in clinical trials to
varying efficacy (Clinical Trial: NCT02080364 for TTP488 was terminated due to lack of
efficacy) (271, 272), however it is unclear whether they specifically block the region of this
complex binding PRR where S100A9 binds, or if they specifically just block the region in
which advanced glycation endproducts and amyloid beta plaques bind. Development of
a RAGE inhibitor that conformationally binds at the S100A9-binding site is thus crucial.
Alternatives are the developments of S100A9 neutralizing antibodies for clinical use. This
would perhaps be a broader spectrum approach for multiple malignancies since S100A9
is implicated in various pathologies.
The work reported here lays the groundwork for future studies of basic and
translational immunology in a disease where this arm of the immune system is virtually
untouched outside of the realm of therapeutics. Although adoptive cell therapies are at
the forefront of everyone’s mind, it is still of great importance to consider ways to
reinvigorate the autologous immune system, since the only real curative therapy is
allogeneic bone marrow transplant, a therapy which is high-risk, high-reward.
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RESEARCH INTEGRITY AND COMPLIANCE
INSTITUTIONAL ANIMAL CARE & USE COMMITTEE
MEMORANDUM
TO:

Sheng Wei,

FROM:
Farah Moulvi, MSPH, IACUC Coordinator
Institutional Animal Care & Use Committee
Research Integrity & Compliance
DATE:

5/14/2019

PROJECT TITLE:

Nanoparticle-based targeting of miR183 for immunotherapy of lung cancer

FUNDING SOURCE:

Florida Department of Health
James and Esther King Biomedical Research Program

IACUC PROTOCOL #:

R IS00005998

PROTOCOL STATUS:

Amendment APPROVED

The Institutional Animal Care and Use Committee (IACUC) received your Modification concerning the
above referenced IACUC protocol.
On 5/14/2019 the IACUC reviewed and approved your Modification for the following:
Modification: Amendment Request for IACUC Study 2.1.1
Added: Additional strain of approved species
Modification: Additional Strains 2.5.1
B6.Cg-Mir155tm1Rsky/J (https://www.jax.org/strain/007745)
We are in the process of peer review for one of our publications and the reviewers require that we
use splenocytes for two experiments similar to what we have carried out in the past and currently
under this protocol. The mice will not be experimented on but immediately euthanized and used for
tissues.
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INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE
PHS No. A4100-01, AAALAC No. 000434, USDA No. 58-R-0015
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IRB APPROVED DOCUMENTATION:
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Protocol (Version Date: 4/26/19)

The IRB approved the above referenced protocol and your site on 20 May 2019.
The IRB determined above referenced study met the criteria for a Waiver of Consent per 45 CFR
46.116(d) and a Waiver of HIPAA Authorization per 45 CFR 164.512(i)(2). The IRB granted the Waiver
of Consent and Waiver of HIPAA Authorization.
If the study is expected to last beyond the approval period, you must request and receive re-approval prior to
the expiration date noted above. A report to the Board on the status of this study is due prior to the expiration
date or at the time the study closes, whichever is earlier. It is recommended that you submit status reports at
least 4 weeks prior to your expiration date to avoid any additional fees or lapses in approval.
Approved investigators and sites are required to submit to Advarra for review, and await a response prior to
implementing, any amendments or changes in the protocol; informed consents; advertisements or recruitment
materials ("study-related materials"); investigators; or sites (primary and additional).
Approved investigators and sites are required to notify Advarra of the following reportable events, including,
but not limited to: unanticipated problems involving risks to subjects or others; unanticipated adverse device
effects; protocol violations that may affect the subjects’ rights, safety, or well-being and/or the completeness,
accuracy and reliability of the study data; subject death; suspension of enrollment; or termination of the study.
Please review the IRB Handbook located in the “Reference Materials” section of Advarra CIRBI™ Platform
(www.cirbi.net). A copy of the most recent IRB roster is also available.
Thank you for selecting Advarra IRB to provide oversight for your research project.
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